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The development of resistance to chemotherapy is a recurrent and serious problem applicable 
to many types of cancer including ovarian cancer, which can show intrinsic and acquired 
resistance to first-line chemotherapy such as platinum-based drugs (e.g. cisplatin, 
carboplatin) and taxanes (e.g. paclitaxel), and for the anthracyclines (e.g. doxorubicin). 
Plants have been a source of therapeutic agents for various diseases for thousands of years, 
the taxanes being an example. Frankincense (from Boswellia sp.) has been used in traditional 
medicine for centuries. Bioactive components (primarily boswellic acids) responsible for the 
therapeutic actions of frankincense have been investigated and characterised in many cases, 
although activity against selected cancer types, ability to synergise with existing therapies 
and to overcome chemoresistance is not as well explored. The identification of individual 
components in frankincense that can synergise or otherwise yield unexpected anti-cancer 
effects may yield useful information that can be exploited for therapy and give additional 
insight into mechanisms of cancer chemoresistance. 
This project explores the potential utility and mechanisms of action of 3-O-acetyl-11-keto-β-
boswellic acid (AKBA), a bioactive component of frankincense, in counteracting 
chemoresistance in cancer, using ovarian cancer as the primary model. The work was 
conducted in vitro using sensitive and resistant ovarian cancer cell lines and a range of cell 
and molecular biology approaches to determine the effect and mechanisms of action of 
AKBA on ovarian cancer cells. This included cell viability assay, cell cycle analysis, 
mitochondrial membrane potential (Δψm) assay (apoptosis) and protein expression analysis to 
help examine mechanism of action of AKBA. 
The key finding of this study is the synergistic interaction between AKBA and doxorubicin, 
which could consequently lead to reduction of doxorubicin dose and the side effects,. The 
difference between the EC50 values of doxorubicin in the presence or absence of AKBA were 
statistically significant. Alterations in the Δψm and the inhibition of NFκB (nuclear factor 
kappa-light-chain-enhancer of activated B cells) pathway by supressing the expression of 
multiple proteins seem to be among the mechanisms of action behind the ability of AKBA to 
sensitise cancer cells to doxorubicin. An apparent antagonistic interaction was reported 
between AKBA and cisplatin, on A2780, A2780cis and OVCAR4 cells. The same was 
observed with paclitaxel on A2780cis, however, the resulting interaction on A2780 was 
additive. Further studies to understand or overcome these antagonistic interactions are 
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required. Despite the limitations, current findings indicate that bioactive components of 
frankincense could help in overcoming resistance in cancer cells and enhance the efficacy of 
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List of abbreviations  
- 5-LO   5-lipoxygenase 
- A2780   Ovarian endometroid adenocarcinoma cells 
- A2780ADR   Doxorubicin resistant A2780 
- A2780cis   Cisplatin resistant A2780 
- ABA    3-O-acetyl-β-boswellic acid 
- ABCF2   ATP-binding cassette subfamily F member 2 
- AEG-1   Astrocyte elevated gene 1/metadherin 
- AKBA   3-O-acetyl-11-keto-β-boswellic acid 
- Akt    Protein kinase B (PKB) 
- APAF1   Apoptotic protease -activating factor-1 
- ARE   Antioxidant-response element  
- ARID1A  AT-rich interactive domain-containing protein 1A 
- ASC   Apoptosis-associated speck-like protein containing a CARD 
- ATP   Adenosine triphosphate 
- BA   Boswellic acid 
- BCL-10  B-cell lymphoma/leukemia 10 
- BCRP/ABCG2  Breast cancer resistance protein  
- BRAF   B-Raf proto-oncogene serine/threonine-protein kinase 
- BRCA1/2  Brest cancer genes 1 and 2 
- BSE   Boswellia serrata extract  
- CARD6  Caspase recruitment domain-containing protein 6 
- CCC   Clear-cell carcinoma 
- CCRF-CEM  lymphoblastic leukemia 
- CD40/TNFRSF5 Cluster of differentiation 40/TNF receptor superfamily member 5 
- Cdc   Cell division control protein 
- CDK   Cyclin-dependent kinase 
- CDK12   Cyclin-dependent kinase 12 
- CI   Combination index 
- cIAP1/2  Cellular inhibitor of apoptosis protein 1/2 
- CML   chronic myeloid leukemia 
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- COX-2   cyclooxygenase 2 
- CSC   Cancer stem cells 
- CTNNB1  Catenin (cadherin-associated protein), beta 1 
- CXCR4  C-X-C Motif Chemokine Receptor 4 
- CYPs   Cytochrome P450 enzymes 
- DCFDA   2’,7’ –dichlorofluorescin diacetate  
- DMSO   Dimethyl sulfoxide 
- DNA   Deoxyribonucleic acid 
- DR5   Death receptor 5  
- EC   Endometrioid carcinoma 
- EOC   Epithelial ovarian carcinoma 
- ER/UPR  Endoplasmic reticulum/unfolded protein response 
- FADD   FAS-associated death domain protein 
- FasR/Fas  Fas cell surface death receptor 
- FDA   Food and Drug Administration 
- FEc/FEo  Clear frankincense extract/oily frankincense extract 
- FTH1   Ferritin heavy chain 
- FTL    Ferritin light chain 
- FUCCI   fluorescence ubiquitination cell cycle indicator 
- G6PD    Glucose-6-phosphate dehydrogenase 
- GCL    Glutamate cysteine ligase 
- GPx    Glutathione peroxidase 
- GSH    Glutathione 
- GSTA2   Glutathione S-transferase A2 
- GSTs    Glutathione S-transferases 
- H2O2    Hydrogen peroxide 
- HCT-116  Human colon carcinoma cells 
- Hep G2   Human hepatocellular carcinoma cells 
- Hep3B   Human hepatocellular carcinoma cells 
- HER2   Human epidermal growth factor receptor 2 
- HGSOC  High-grade serous ovarian cancer 
- HL-60   Human leukaemia cells 
- HNF1   Hepatic nuclear factor 1 
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- HNPCC  Hereditary nonpolyposis colorectal carcinoma 
- HO-1   Heme Oxygenase 1 
- HPLC   High performance liquid chromatography 
- HRP   Horseradish peroxidase 
- HT29   Human colorectal adenocarcinoma cell line 
- IKK   I kappa B kinase   
- IKK   Inhibitor of nuclear factor kappa-B kinase 
- IL-1 R1   Interleukin 1 receptor1 
- IL-17 RA  Interleukin 17 receptor A 
- IL-18 R alpha  Interleukin 18 receptor alpha 
- IL-6   Interleukin 6 
- IRAK1   Interleukin 1 receptor associated kinase 1 
- IRF5   Interferon regulatory factor 5 
- IRF8   Interferon regulatory factor 8 
- IV   Intravenous 
- IκB   Nuclear factor of kappa light polypeptide gene enhancer in B-cells 
inhibitor 
- JNK   c-Jun N-terminal kinase 
- KBA    11-keto-β-boswellic acid 
- KRAS   Kirsten rat sarcoma viral oncogene homolog 
- LGSOC  Low-grade serous ovarian carcinoma 
- LLOQ    Lower limit of quantitation  
- LNCaP  Human prostate adenocarcinoma cells 
- LoVo   Human colorectal adenocarcinoma cells 
- LS174T  Human colorectal adenocarcinoma cell line 
- LTBR/TNFRSF3 Lymphotoxin-beta receptor/tumour necrosis factor receptor 
superfamily member 3 
- M1   A subtype of macrophages 
- MC   Mucinous carcinoma 
- MDA-MB-231  Adenocarcinoma cells 
- MDR1/ABCB1/P-gp Multi drug resistance gene/ Permeability glycoprotein  
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- MMP-9  Matrix metallopeptidase 9 
- MRPs    Multidrug resistance associated proteins  
- MTT   3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
- MYD88  Myeloid differentiation primary response 88 
- NCS   Newborn calf serum 
- NF-κB   Nuclear factor kappa-light-chain enhancer of activated B-cells 
- NF1   Neurofibromin 1 
- NFκB    Nuclear factor kappa-light-chain-enhancer of activated B cells 
- NGF R   Nerve growth factor receptor 
- NQO1   NAD(P)H: quinine oxidoreductase 1 
- NQO1   NADPH: quinone oxidoreductase 1 
- Nrf2   Nuclear factor e2-related factor 2  
- OVCAR4  Ovarian adenocarcinoma cell line 
- p53   Tumour protein p53  
- PBS   Phosphate buffered saline 
- PC-3   Human prostate cancer cells 
- PC3/Doc  Human prostate cancer cells (docetaxel-resistant) 
- PI   Propidium iodide 
- POI3KCA  Phosphatidylinositol 3-kinase 
- PPP2R1A  Protein Phosphatase 2 (Formerly 2A), Regulatory Subunit A (PR 65), 
Alpha Isoform 
- Prx1   Peroxiredoxin 1 
- PTEN   Phosphatase and tensin homolog 
- Rb   Retinoblastoma protein 
- RF   Resistance factor 
- RNA   Ribonucleic acid 
- ROS   Reactive oxygen species 
- SEM   Standard error of the mean 
- SHARPIN  Shank-associated RH domain-interacting protein 
- SK-OV-3  Ovarian adenocarcinoma  
- SOCS-6  Supressor of cytokine signalling 6 
- Srx1   Sulfiredoxin 1 
- Stat    Signal transducer and activator of transcription  
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- STING   Stimulator of interferons genes 
- TBS   Tris buffered saline 
- TLC   Thin layer chromatography 
- TNF   Tumour necrosis factor 
- TRAIL   TNF-related apoptosis-inducing ligand 
- TRAIL R2   Tumour necrosis factor-related apoptosis-inducing ligand receptor 1 
- Trx1   Thioredoxin 1 
- TrxR    Thioredoxin reductase 
- Trypsin-EDTA   Trypsin-ethylenediaminetetraacetic Acid 
- UGT    Uridine 5′-diphosphoglucuronosyltransferase 
- UV    Ultraviolet 
- UWB1.289  BRCA1-null human ovarian cancer cell line 
- VEGF   Vascular endothelial growth factor 
- WHO   World Health Organisation 
- β-BA    β-boswellic acid 













In 2012 and 2013 the incidence rate of cancer was 14 million worldwide (WHO, 2017) and 
more than 300,000 new cases in the UK (Cancer Research UK, 2013). More than 8 million 
deaths were reported to be caused by cancer around the world in 2012, where lung cancer 
was ranked at the top of the list as a leading cause of about 1.5 million deaths (WHO, 2017). 
Understanding cancer is crucial for prevention and to improve quality of life and survival 
rates of patients.  
Cancer is a complex genetic disease initially and simply defined as uncontrolled cellular 
growth. Cancer develops as a complex multi-step process, illustrated and expanded by 
Hanahan and Weinberg (2000, 2011), who introduced the hallmarks of cancer that can be 
divided into two categories: enabling and ability characteristics (Petrillo et al., 2016) (see 
Table 1.1). In addition, the complexity of cancer increases by knowing that more than one 
cell type is involved in the growth and maintenance of a tumour and contributing to tumour 
progression forming what is widely known as the “tumour microenvironment” (see Figure 4 
in Hanahan and Weinberg (2011)). This complexity could be one of the reasons behind 
chemoresistance and cancer recurrence. 
Table 1.1: Categorisation of the hallmarks of cancer 
Cancer enabling characteristics Cancer ability characteristics 
Genomic instability 
Inflammatory state 
Sustained proliferative signaling 
Evasion of growth suppressors 
Evasion of immune destruction  
Replicative immortality  
Resistance to cell death 
Angiogenesis 
Activation of invasion and metastasis 
Energy metabolism 
* Based on Petrillo et al. (2016) and Hanahan and Weinberg (2000, 2011)  
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1.1.1 Ovarian cancer 
Understanding of epithelial ovarian cancer (EOC) is crucial considering its high mortality 
rate. It is the 4th leading cause of cancer related deaths in women in developed countries 
(Jayson et al., 2014) and the primary cause of gynaecologic cancer related deaths in women 
(Bagnato and Rosanò, 2012). In 2014, more than 7,000 women were diagnosed with ovarian 
cancer in the UK, where the reported number of deaths was more than 4,000 cases (55 %) 
(Cancer Research UK, 2014). The estimated figures for ovarian cancer in 2017 in the USA 
are 22,440 new cases with 14,080 deaths caused by the disease (American Cancer Society, 
2017). Ovarian cancer can originate from the epithelium (∼ 90%), germ cells (∼ 5%) and 
stromal cells (∼5%) (Figure 1.1), however, the topic is still debatable (Shield et al., 2009). 
The following sub-types of EOC are recognised: serous, endometrioid clear, cell mucinous, 
or undifferentiated/unclassifiable (Cancer Research UK, 2016). The current histologic 
classification of EOC (Table 1.2) for research purposes are type I and type II. Type I tumours 
include low-grade serous, low-grade endometrioid cancers, mucinous, clear cell, and 
transitional cell carcinomas. Type II include high-grade serous, high-grade endometrioid 
carcinomas, carcinosarcomas and undifferentiated carcinomas, which are known for their 
aggressiveness with late stage diagnosis (Cobb et al., 2015). It is important to indicate that 
peritoneal cancer and fallopian tube cancer are considered clinically as ovarian cancers for 






Table 1.2: Characteristics of common EOC  
 HGSOC LGSOC MC EC CCC 
Incidence 
% of EOC 
70 % <5 % 3 % 10 % 10 % 
Risk 
Factors 





















Usually confined to ovary Usually confined to 
pelvis 
Usually confined to pelvis 
Associated 
mutations 




KRAS, HER2 PTEN, ARID1A, 
aPI3KCA, 
aPPP2R1A  
HNF1, ARID1A, aPI3KCA, aPTEN, 
aCTNNB1, aPPP2R1A 
HGSOC, high-grade serous ovarian carcinoma; LGSOC, low-grade serous ovarian carcinoma; MC, mucinous carcinoma; EC, endometrioid carcinoma; CCC, clear-cell carcinoma. 
*Hereditary nonpolyposis colorectal carcinoma. 
a(Jayson et al., 2014). 





Figure 1.1: Ovarian cancer. (Shutterstock ID: 147789488) 
Where EOC is diagnosed late in an advanced stage (stage III), EOC is difficult to treat 
(Jayson et al., 2014). Although the detection of the disease in earlier stages has shown certain 
improvements in the last few years, EOC disseminates in the early stages to pelvic and 
abdominal organs and in an unusual way compared to the other epithelial cancers, in that 
EOC does not usually require the vasculature to disseminate (Shield et al., 2009). In addition, 
the hallmarks of cancer have been successfully applied for ovarian cancer. Ovarian cancer is 
a heterogeneous group of related diseases with distinctive molecular profiling and 
histological variations (Goff, 2013). This information gives an idea of the prospects for 
survival time that may result from EOC and how urgent it is to develop protective strategies 
 20 
and diagnostic techniques, which could reduce the number of patients and help to improve 
the survival rate. 
 
1.1.2 Ovarian cancer treatment 
Similar to other types of cancer, radiotherapy, surgery and chemotherapy are the key 
strategies to treat ovarian cancer. First line chemotherapy is usually given every two to three 
weeks as a combination of a platinum compound, such as cisplatin, and a taxane, such as 
paclitaxel (Bell and Lutman, 2010). The development of resistance to chemotherapy is a 
recurrent and serious problem applicable to many types of cancer; ovarian cancer is a 
particular tumour type that can show intrinsic and acquired resistance to first-line 
chemotherapy (Kigawa, 2013). Recurrent ovarian cancer is usually sensitive to platinum 
drugs. Therefore, a combination of platinum containing drugs and liposomal doxorubicin for 
example is recommended for the recurrent disease (Jayson et al., 2014). Armstrong et al. 
(2012) stated that it is more difficult to overcome chemoresistance that arises from combined 
platinum agent and taxane therapy. 
The new advances in the understanding of the distinct molecular characteristics of EOC 
histologic sub-types is leading to promising molecularly-targeted treatments. This may lead 
to more selective and less toxic agents compared to current chemotherapies (Banerjee and 
Kaye, 2013). As stated by Banerjee and Kaye (2013), the historic approaches of treatment 
considered the sub-types as one entity despite the molecular differences which emerged later. 
 
1.1.3 The molecular mechanisms of action of cisplatin, paclitaxel and doxorubicin 
Exploring the mechanisms of action of chemotherapies could help in understanding and 
overcoming chemoresistance in tumours. The mechanisms of action are usually complex and, 
in some cases, unclear and need further studies to provide the closest possible explanation of 
the agents interaction in the body. This is probably a result of the involvement of a number of 
molecular and cellular changes and even biologically active metabolites in the action of 
chemotherapies. A brief exploration of the mechanisms of action of cisplatin, paclitaxel and 




Cisplatin (cis-Diamminedichloroplatinum(II)) (Figure 1.2) is a well known potent anti-
tumour agent that was accidently discovered from platinum electrodes in the 1960s. Dr. 
Rosenberg and his colleagues noticed that E. coli bacteria stopped dividing, when they run 
electrical current in a solution that contains the bacteria using platinum electrodes. It was first 
used as an antibacterial agents then was shown to be effective against tumours. The first 
reported clinical trial was conducted in 1972 where a number of undesirable serious toxic 
effects to the kidney and the bone marrow, for example, were observed. This has led to 
further investigations and developments to the agent and the treatment regimens which 
resulted in the generation of one of the leading anti-cancer agents that was registered in USA 
in 1978, and in Europe and Japan in 1984 (Reedijk and Lohman, 1985; Makovec, 2019). 
Cisplatin has been particularly used to treat bladder, head, neck, lung, ovarian, and testicular 
cancers. It is also potent against various types of cancers including carcinomas of various 
tissue/cell type origin, germ cell tumours, lymphomas, and sarcomas. 
 
Figure 1.2: Cisplatin chemical structure. 
A number of molecular mechanisms, protein and genetic alteration play a role in the toxicity 
caused by cisplatin and its metabolites towards cancer cells. Cisplatin leads to DNA damage 
by various methods including crosslink with the purine bases on the DNA and interferes with 
DNA repair mechanisms which causes DNA damage, blocks DNA replication and induces 
apoptosis in cancer cells. Increasing cellular oxidative stress is another mechanism of 
cisplatin toxicity which target the mitochondria and leads to loss of mitochondrial protein 
sulfhydryl groups, calcium uptake inhibition and reduction of mitochondrial membrane 





Doxorubicin (adriamycin) (Figure 1.3) is another good example of the medicines that were 
extracted from natural sources. It belongs to a family of antibiotics and chemotherapies called 
anthracycline. The discovery of doxorubicin goes back to the late 1960s from a mutant strain 
of Streptomyces peucetius. Discovery occurred when researchers worked on developing new 
strains of S. peucetius looking for new antitumor agents following the success of the isolation 
of daunorubicin from the wild S. peucetius that showed clinical importance for leukaemia 
(Arcamone et al., 1969; Lomovskaya et al., 1999). 
 
Figure 1.3: Doxorubicin chemical structure 
Similar to other chemotherapies, the mechanism of action of doxorubicin is complex and 
affects a number of molecular targets. The commonly known mechanisms involve the 
interfering with DNA synthesis through intercalation and inhibiting topoisomerase II. 
Stabilising topoisomerase II prevents resealing the double helix DNA leading to the 
interruption of the DNA replication. The other mechanism is the induction of free radicals 
that causes DNA and cellular damage, where reduction or oxidation of doxorubicin can 
induce intracellular hydrogen peroxide generation (H2O2). These mechanisms in addition to 
membrane lipid oxidation and the inhibition of the respiratory chain enzymes in mitochondria 
lead to the induction of apoptosis (Müller et al., 1997; Mizutani et al., 2005; Pilco-Ferreto 
and Calaf, 2016; Falzone, Salomone and Libra, 2018). 
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1.1.3.3 Paclitaxel (Taxol®) 
The history of discovering paclitaxel (Figure 1.4), among other plant based medicines, serves 
as an example that indicates to the importance of plants as a source of therapeutic agents. 
Paclitaxel was extracted from the bark of Taxus brevifolia (Pacific Yew) in the USA as part 
of a screening program that was exploring the plant kingdom for antitumor agents which 
started in 1960. Drs Wall and Wani were interested in studying the bark of T. brevifolia 
following their earlier success in isolation of camptothecin from a Chinese tree (Happy Tree), 
Camptotheca acuminata, which was potent against L1210 mouse leukaemia cell line in vitro. 
Taxol is a secondary metabolite that is isolated through bioactivity-guided determination in a 
multi-step isolation process. After a decade of discovering and developing the agent, TaxolÒ 
was used to treat ovarian cancer which was then followed by reporting its efficacy against 
breast, lung and prostate cancers (Wall and Wani, 1996). 
 
Figure 1.4: Paclitaxel chemical structure 
When it comes to the mechanism of action, paclitaxel arrests cell cycle at G2/M phase by 
stabilizing microtubules and inhibiting their depolymerisation to tubulin which in turns 
blocks mitosis (Wall and Wani, 1996) through activating the mitotic checkpoint. This 
observation was reported by a number of researchers at high doses of paclitaxel in cell 
culture, nonetheless the apparent mechanism was the induction of multipolar spindles in 
breast cancer cell lines when clinically relevant doses were tested, 5-50 nM in cell lines to 1-




Chemotherapy, in addition to the other two strategies: surgery and radiotherapy, is a major 
component of the conventional treatment of cancer. However, the efficacy of chemotherapy 
is limited due to the ability of cancer to resist the therapy, which can be intrinsic or acquired 
(Wilson, Longley and Johnston, 2006; Chang, 2011). While the acquired resistance occurs 
due to the genetic adaptation of cancer cells in response to the stress that imposed by 
chemotherapies, intrinsic resistance can arise before or during the early stages of 
tumorigenesis without the need for cells to be completely transformed. Expression of hTERT 
(Telomerase reverse transcriptase) and inactivation of pathways that are regulated by pRb 
and p53 are the minimum genetic alterations that allow primary cells to be chemoresistant 
(Raguz and Yagüe, 2008). Acquired resistance in solid tumours could potentially occur 
within a short period of time (hours/days) following the treatment, which involves 
overexpression of resistance genes such as multi-drug resistance gene I (MDR-I), also known 
as permeability glycoprotein (P-gp), or down-regulation in target genes, e.g. topoisomerase 
IIα (Di Nicolantonio et al., 2005). P-gp expression and function was increased after 16 hours 
of ex vivo exposure of acute and chronic myeloid leukemic blasts to a number of 
anthracycline analogues or cytosine arabinoside (Hu et al., 1999). The level of MDR-I RNA 
was increased following 50 minutes in vivo exposure to doxorubicin in patients with 
metastatic sarcoma (Abolhoda et al., 1999). P-gp role in chemoresistance will be discussed in 
chapter 5. 
Chemoresistance contributes to the treatment failure in more than 90 % of the cases of 
metastasised disease (Wilson, Longley and Johnston, 2006), which indicates to the 
importance of understanding of the mechanisms behind this phenomenon. Efflux of the 
chemotherapeutic agent from the tumour cell; modification of drug targets; changes or 
mutation in mitotic checkpoint signals; drug sequestration; de-toxification of cytotoxic 
agents; and enhanced DNA repair mechanisms are the cellular mechanisms that have been 
established in chemoresistance of cancer to a number of therapeutic agents (Chang, 2011). 
One or more of these mechanisms could be found in a particular tumour type because of 
cellular heterogeneity in cancer (Vasey, 2003). 
Most of the available cytotoxic chemotherapies target cells that are rapidly dividing, which 
could be one of the reasons that leads to cancer relapse and chemoresistance. Changes in the 
rate of proliferation were investigated and reported to be lower, in many cases of single and 
dual resistant cancer cell lines, than their sensitive counterpart (Armstrong et al., 2012). In 
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addition, it was demonstrated that invading cells are in phases G0/G1 of mitosis using real-
time FUCCI (fluorescence ubiquitination cell cycle indicator) imaging (Yano et al., 2014).  
On the other hand, cytotoxic drugs are therapeutically effective against solid tumours, even 
though it was reported that solid tumours are generally slow in terms of proliferation. This 
paradox was explored by Mitchison (2012) using paclitaxel on solid tumours in mice. It was 
reported that cells died after days of treatment despite the fact that they had not entered 
mitosis nor were they proliferating, whereas the expected result by induction of mitotic arrest 
followed by apoptosis was observed in less than 25 % of cells. This brings forward the recent 
concept of quiescent, so called cancer stem cells (CSC), cells that was introduced as one of 
the reasons for chemoresistance.  
 
1.1.5 Cancer stem cells (CSCs) 
Recently, the hypothesis of the existence of CSCs in cancer and their role in cancer initiation 
and the ability of cancer to resist chemotherapies has been under investigation. In the original 
model for tumour initiation, every single cell in a heterogeneous tumour has the ability to 
regenerate a tumour which is called the stochastic model. The other model is called 
hierarchical or CSC model, where the ability to initiate a tumour is possessed by a small 
population of cancer cells (Tirino et al., 2013). This population could be a result of genetic 
and/or epigenetic alterations of adult stem cells, which enable them to transform and 
metastasise to other organs or tissues (Davis, Tinker and Friedlander, 2014).  
The presence of CSCs in various types of cancers such as chronic myeloid leukaemia (CML), 
brain and gastrointestinal tumours was demonstrated in several studies (Raguz and Yagüe, 
2008). Stem cells were also found in ovarian cancer and were related to its aggressiveness 
(Bapat et al., 2005). To differentiate CSCs from other cells in cancer, a number of defining 
characteristics were stated. This includes enhanced tumour initiating potential and stem-like 
properties that are self-renewal and the ability to differentiate to another tumour cell sub-type 
(Abdullah and Chow, 2013). In addition, the ability of CSCs to remain quiescent for a long 
time, and survive the harsh environments and cytotoxic drug insult indicate to the possible 
role of CSCs in chemoresistance and tumour relapse (Tirino et al., 2013). Enhanced DNA 
repair mechanisms and expression of detoxifying aldehyde dehydrogenase enzymes are 
among the mechanisms that were reported for CSCs to resist chemotherapies (Thomas et al., 
2014). 
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1.1.6 The side effects of chemotherapies 
Despite the fact that chemotherapies have been and still are one of therapeutic approaches to 
treat cancer, there are a number of serious undesirable side effects on normal cells and 
tissues. Numerous side effects are linked to cisplatin including, but not limited to, 
neurotoxicity and nephrotoxicity. Nephrotoxicity is noticeable and clinically significant 
where developing acute renal failure is estimated to happen in about 30 % of the patients 
after receiving dose of 50 -100 mg per/m2 cisplatin (Barabas et al., 2008; Barton et al., 2018). 
With regards to paclitaxel, the main side effects include serious hypersensitivity, 
nephrotoxicity and neurotoxicity (Koudelka and Turánek, 2012). Finally, the major known 
side effect of doxorubicin is cardiotoxicity (Wortman et al., 1979; Kalyanaraman et al., 2002; 
Hershman et al., 2007). Therefore, a number of approaches have been established and are 
still under development and investigation to reduce the side effects of chemotherapies. This 




Plants have been a source of therapeutic agents for various diseases for thousands of years, 
the taxanes, leading to the development of tamoxifen for the treatment of breast cancer being 
an example. Traditional medicine is based predominantly around the use of selected plant 
components delivered as mixtures, often taken orally. Frankincense (from Boswellia sp.) 
(Figure 1.5) has been used in traditional medicine for centuries. It has been used to treat 
‘fever, skin diseases, rheumatism, respiratory diseases including laryngitis and cough with 
copious amounts of sputum, liver disorders, ringworm, boils, strengthening of teeth, healing 
eye inflammations, enhancing the growth of hair, improving appetite, wound healing, 
soothing mouth sores, improving diarrhoea, general restorative, tonic effects and more’ 
(Rentea, 2008). Frankincense is a French word that means pure incense which has also been 
used in religious and cultural events in various cultures and societies (Ammon, 2006). Indian 
olibanum, Salai guggal, Loban, or Kundur are other popular names of frankincense. The 
trunk of Boswellia trees produces an oleogum resin in response to scrapes or wounds to 
prevent infection and heal (Garg and Deep, 2016).  
 
 
Figure 1.5: Boswellia tree and frankincense olibanum resin. (https://commons.wikimedia.org) 
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1.2.1 Composition and biological activity 
Oleogum resin contains more than 200 compounds with variability in terms of contents 
depending on the species, harvestings and the tree location (Ammon, 2006). Volatile oils (5–
15%), pure resin (55–66%) and mucus (12–23%) are the main components of oleogum resin 
(Tawab et al., 2011). Triterpenes, such as pentacyclic and tetracyclic triterpenes, are among 
the terpenes that compose the resin. Pentacyclic bioactive components (primarily boswellic 
acids, BAs) responsible for the therapeutic actions of frankincense have been investigated 
and characterised in many cases (Hamidpour et al., 2016), although activity against selected 
cancer types, ability to synergise with existing therapies and to overcome chemoresistance is 
not as well explored. 
β-boswellic acid (β-BA), acetyl-β-boswellic acid (ABA), 11-keto-β-boswellic (KBA) acid 
and 3-O-acetyl-11-keto-β- boswellic acid (AKBA) are examples of the main bioactive 
boswellic acids (BAs) that have been found in frankincense (Table 1.4). Inhibition of pro-
inflammatory enzymes has been reported to be one of the effects of these boswellic acids 
(Hamidpour et al, 2016). AKBA, in particular, has shown a strong anti-inflammatory effect 
by inhibiting 5-lipoxigenase, which has been found to be overexpressed in a number of 
chronic diseases including chronic inflammation, cardiovascular diseases and cancers 
(Rentea, 2008). Moreover, inhibitors of 5-LO are suggested to be part of chemoprevention 
strategies of various types of cancers due to its contribution to cell proliferation and apoptosis 
inhibition (Garg and Deep, 2016). In contrast to AKBA and KBA, which are selective, 
potent, non-redox and non-competitive inhibitors of 5-LO, most available enzyme inhibitors 
lead to undesirable side effects for being non-selective (Kaunzinger et al., 2002). Despite this 
selectivity and potentiality towards 5-LO in vitro, the pharmacological relevance of this 
effect in vivo is implausible (Siemoneit et al., 2009), which could be attributed to the issues 
related to the bioavailability of AKBA (see 1.2.3). 
In addition to BAs, essential oils have been reported to be cytotoxic towards tumour cells. 
For example, Ni et al. (2012) demonstrated the cytotoxicity of various fractions of essential 
oils, that have been prepared from hydrodistillation of Boswellia sacra gum resins, on 
pancreatic cancer. Essential oils in the fractions with high molecular weight were toxic to and 
induced apoptosis through caspase dependent pathway on pancreatic cancer cells. Although 
the fractions with high concentration of BAs (19.6 and 30.1 mg/mL) were considered more 
potent than the others (0.81 and 0.91 mg/mL), the latter were reported to be cytotoxic. This 
could mean that there are anti-tumour compounds in frankincense other than BAs. 
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1.2.2 The molecular targets of boswellic acids 
There are multiple established molecular targets of boswellic acids in chronic diseases, 
including cancer, which could be linked to their various biological activities. The targets are 
enzymes, growth factors, transcription factors, kinases and others involved in cell survival 
and proliferation (Table 1.3). For example, AKBA arrested cells at G1 and downregulated 
cyclin-dependent kinases (CDKs) through p53-independent upregulation of p21 CDK 
inhibitor in colon cancer cell lines, HCT-116, HT29 and LS174T (Khan et al., 2016; Roy et 
al., 2016, 2019). This variation and multiplicity could explain the potentiality of boswellic 
acids and frankincense extracts in cancer prevention and treatment. The multiplicity of 
molecular mechanisms targeted by boswellic acids on a variety of cancer cell lines was 
reported on a genetic level using mRNA-based microarray, COMPARE (Eichhorn, Greten 
and Efferth, 2011). 
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Table 1.3: Non exhaustive list of published molecular targets of Boswellia serrata extract (BSE) and BAs in cancer 
Extracts/Compound Cancer type and used model Molecular target/Mechanism Reference 
BSE and/or ABA Breast cancer: MDA-MB-231 
cells 
↑ ER/UPR response (Mazzio, Lewis and 
Soliman, 2017) 
KBA and AKBA Liver cancer: Hep G2 cells ↑ Caspase-3 & -8 (Liu et al., 2002) 
BSE Liver cancer: HepG2 and 
Hep3B cells 
↑ caspase-3, TNF-! and IL-6 (Khan et al., 2014) 
AKBA Pancreatic cancer: several cell 
lines and a mouse model 
↓ NFκB , NFκB regulating 
genes, COX-2, MMP-9, 
CXCR4, and VEGF 
(Park et al., 2011) 
BSE and AKBA Colorectal carcinoma: LoVo 
and HT29 cells 
↓ NFκB phosphorylation (Catanzaro et al., 
2015) 
AKBA Prostate cancer: PC-3 and 
LNCaP cells 
↑ Caspase-3 & -8,  DR5 and 
PARP cleavage 
(Lu et al., 2008) 
AKBA Prostate cancer: PC-3 cells ↓ IKK and NFκB  (Syrovets et al., 
2005) 
AKBA Prostate cancer: PC3/Doc 
(docetaxel-resistant) 
↓Akt and Stat 3 (Liu et al., 2019) 
AKBA Leukemia: HL-60 and CCRF-
CEM cells 
↓ Topoisomerases I (Hoernlein et al., 
1999) 
 
1.2.3 Bioavailability of natural products 
The poor bioavailability of natural bioactive compounds and herbal extracts following oral 
administration is one of the main challenges that limit the use of natural remedies in clinical 
settings. Oral administration is widely preferred over other routes, such as intravenous (IV), 
for the following advantages: painlessness, easy self-administration, high patient compliance, 
and feasibility for outpatients (Lin et al., 2017). Solubility and/or dissolution, permeation, 
first-pass metabolism, and pre-systemic excretion or efflux are the oral bioavailability 
barriers (Hu and Li, 2011). Despite the promising reports of a number of a number of natural 
products as cancer chemopreventive agents discussed in the review by Gao et al. (2013), the 
bioavailability of the agents in vivo and in pre-clinical studies was much lower than the 
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required doses to exert the desired effects (Gao et al., 2013). This was linked to one or more 
factors such as poor solubility in water and/or rapid/extensive metabolism. 
A number of approaches were investigated to enhance the oral bioavailability of natural 
products based on the understanding of the reasons behind the poor oral bioavailability of a 
particular agent. This include, non-exhaustively, adjuvants, nanoparticles, and liposomes, 
micelles, and phospholipid complexes, and analogues and derivatives (Anand et al., 2007; 
Gupta et al., 2013).  For example, curcumin, a bioactive component from turmeric, 
bioavailability was reported to increase by 2000 % when it was combined with piperine, a 
bioactive component from black pepper (Gupta et al., 2013; Hewlings and Kalman, 2017). 
Further research is still needed to overcome this issue. 
The discussed poor oral bioavailability of natural products propose the question about the 
efficacy of using other administration routes, such as IV, intraperitoneal and topical 
application…etc., on natural compounds bioavailability. Poor solubility, rapid metabolism 
and/or elimination, as examples, stand as obstacles against achieving required doses despite 
the reported improved plasma concentration and area under curve (AUC) of some natural 
compounds after IV administration compared to oral administration (Das et al., 2008; 
Kapetanovic et al., 2011; Estrela et al., 2017). Taking into consideration the aforementioned 
challenges of IV administration of natural products, it could be used to avoid gastrointestinal 
barriers, although primary tumours of the gastrointestinal tract could be treated with effective 
natural products orally (Estrela et al., 2017). In addition, it was reported that topical 
application of resveratrol, a naturally occurring polyphenol, could protect against ultraviolet 
radiation-induced skin cancer (Xiao et al., 2019). 
The solubility of natural bioactive compounds is one of the challenges that limits their 
bioavailability. Dimethyl sulfoxide (DMSO) is a solvent that is wieldy used to dissolve a 
broad range of both polar and non-polar poorly soluble compounds. It is also commonly used 
as a vehicle and/or a therapeutic agent in laboratory studies and clinical practice. This 
includes, non-exhaustively, cryopreservation, free radical scavenging, inducing anti-
inflammation, muscle relaxation and penetration enhancer in topical application. DMSO is 
generally considered nontoxic if it is below 10 % (v/v) and is classified as class 3 with 
ethanol and other solvents by United States Food and Drug Administration (FDA) in spite of 
the lack of full understanding of its physiological and pharmacological effects (Santos et al., 
2003; FDA, 2012; Costa et al., 2017; Verheijen et al., 2019).  
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On the other hand, a number of side effects and drug interactions were reported questioning 
the safety of DMSO. The reported systemic side effects of DMSO includes nausea, vomiting, 
diarrhea, hemolysis, rashes, renal failure, hypertension, bradycardia, heart block, pulmonary 
edema, cardiac arrest and bronchospasm (Santos et al., 2003). It was reported that 
intraperitoneal administration of DMSO, at 32 and 62 % (v/v) in saline, affected mice 
behavior, which was demonstrated via the significantly decreased locomotor activity (Castro 
et al., 1995). The in vitro effect of DMSO in cell culture systems varies depending on the 
concentrations and cell type (Timm et al., 2013). A wide range of changes in cellular 
processes and epigenetic alterations in in vitro cardiac and hepatic models was observed as a 
result of exposure to DMSO (Verheijen et al., 2019). Although this discrepancy in DMSO 
effects may be linked to the variations in the used concentrations and/or tested models, a 
careful consideration should be taken for every individual application. 
 
1.2.4 Bioavailability of boswellic acids 
Boswellic acids are not an exception of natural products when it comes to limited 
bioavailability. The level of KBA in plasma was 2 µM following oral intake of 1.6 g 
Boswellia extract, while its EC50 to inhibit 5-LO was 2.8 mM (Bagul, Khomane and Bansal, 
2014). They also reported that KBA is not stable in stomach and intestine. Gerbeth et al. 
(2011) reported complete absence of AKBA and low concentration of KBA in the serum of 
13 out of 14 tested volunteers who had taken four capsules of 400 mg Boswellia serrata gum 
resin extract (BSE) three times per day (daily total was 4800 mg). This could be attributed to 
poor retention of the extract in the stomach and intestine or to the fact that tested compounds 
are lipophilic leading to poor absorption, according to the discussed reports. The complete 
absence of AKBA in plasma could also be linked to metabolism in vivo, which will be 
discussed below. 
In a study by Skarke et al. (2012), there was an improvement in the level of KBA after eating 
a standardised meal compared to their level if frankincense was taken in a fasted condition. 
Moreover, the concentration of KBA was higher than the lower limit of quantitation (LLOQ; 
<6.66 ng/mL; coefficient of variation <15%) in both conditions fast and fed, which lasted for 
up to 12h after the intake. This improvement has not been reported for AKBA, but the level 
of AKBA endured above LLOQ for longer time after the fed condition. Both AKBA and 
KBA were reported to be bioavailable in plasma, which contradicts the previously discussed 
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studies. This contradiction might occur for the variations in the used products, physiological 
status between participants or the experimental design. In addition, AKBA was found in 
plasma (454 ± 23 ng/mL) and pancreatic tumour tissue (273 ± 13 ng/mL) in orthotopic nude 
mice 4 h following oral administration of AKBA (Park et al., 2011). AKBA inhibited 
pancreatic tumour growth and metastasis in the orthotopic nude mouse model of pancreatic 
cancer and sensitised cells to gemcitabine (Park et al., 2011). Similar observations were 
reported in rats where the presence of 6 major BAs, including KBA and AKBA, in plasma 
and brain over the period of 8h following oral administration of BSE was confirmed (Gerbeth 
et al., 2013).  
With regards to metabolism, only a few studies considered the metabolic profiles of BAs 
despite their use in pre-clinical and clinical studies, in particular for their anti-inflammatory 
effect, for a relatively long time. It appears that the acetylated BAs, such as AKBA, are 
metabolically stable while non-acetylated BAs, such as KBA, are prone to extensive phase I 
metabolism (Krüger et al., 2008; Gerbeth et al., 2013). In a more recent study that 
investigated the metabolic profile of AKBA and KBA in human preparations in vitro, the 
major metabolic pathway of AKBA was deacetylation to form KBA by carboxylesterase 2, 
whereas KBA was hydroxylated by CYPs, predominantly by CYP3A4 (Cui et al., 2016). 
Moderate anti-inflammatory activity was reported for the formed KBA and hydroxylation 
metabolites compared to their parent compounds (Cui et al., 2016). To our knowledge, there 
is a lack of evidence if metabolism is required for BAs to exert the reported bioactivity. This 
indicates to the importance of further investigations of bioefficacy, bioavailability and 
pharmacokinetics of BSE and individual BAs to develop them as agents in cancer 




R1 R2 Name 
-H 
-OH 
β-boswellic acid (β-BA) 







boswellic acid (AKBA) 
Table 1.4: Chemical structure of BAs 
1.3 Drug Combination 
A combination of two or more drugs is used to treat various diseases including cancer, as 
discussed earlier. A number of studies have investigated the possibility of introducing plant 
extracts as treatments or adjuvants in cancer aiming to either overcome resistance of cancer 
to chemotherapies or to reduce undesirable side effects of the agents. For instance, the vinca 
alkaloid vinblastine (extracted from Catharanthus roseus) is used in combination with 
methotrexate, doxorubicin and cisplatin (MVAC) as an alternative therapy protocol for 
metastasized urothelial cancer. A combination of vinflunine and vinblastine was reported 
effective against gemcitabine- and cisplatin-resistant urothelial cancer cell lines (Vallo et al., 
2015). The synergistic effect between BSE and doxorubicin on human hepatocellular 
carcinoma was studied and reported by Khan et al. (2014). 
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1.4 Aims of the current project 
This project is based on currently unpublished work from Al-Salmani (2017), which indicates 
that the principal bioactive component of frankincense, AKBA, is able to effectively 
decreases the viability of ovarian cancer cells in vitro using models of high grade serous 
ovarian cancer and ovarian endometroid adenocarcinoma, which are OVCAR4, A2780, 
A2780cis and UWB1.289. AKBA cytotoxicity towards tested cell lines was also 
demonstrated through induction of intrinsic and extrinsic apoptotic pathways, the induction 
of DNA damage and decreased ROS generation. Moreover, multiple gene expression 
alterations in the cells were reported following the exposure to AKBA including up-
regulation of pro-apoptotic genes and down-regulation of anti-apoptotic genes. 
Despite the efficacy of conventional chemotherapies, they are linked to serious side effects 
and are challenged with the ability of cancer cells to be resistant. This project aims to explore 
the potential utility and mechanisms of action of AKBA, a bioactive component of 
frankincense, in overcoming chemoresistance in cancer, using ovarian cancer as the primary 
model. This is proposed by establishing the cytotoxic effect of extracts of frankincense 
towards various ovarian cancer cell lines and the ability of the leading bioactive chemical 
component, AKBA, to synergise with selected chemotherapeutic drugs and show preferential 
cytotoxicity towards chemoresistant cancer cells. 
 
1.5 The thesis hypothesis 
The importance of developing new approaches to treat ovarian cancer is urgent for the 
discussed reasons above, which are briefly: the late stage diagnosis, the recurrence of the 
disease, its ability to develop chemoresistance and the undesired side effects of current 
chemotherapies. Since the toxicity of frankincense extracts and bioactive single components 
from it, such as AKBA, towards various cancers were reported, it is hypothesised that AKBA 
will interact synergistically with conventional chemotherapies used to treat ovarian cancer, 
i.e. cisplatin, doxorubicin and paclitaxel. The interaction between AKBA and selected 
chemotherapies will be further explored in terms of the possible mechanisms of actions. The 
other hypothesis is that various extracts of crude frankincense will be toxic towards ovarian 
cancer as they were to other types of cancers, which was not shown on ovarian cancer before. 
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2 Cell viability assessment 
2.1 Introduction 
2.1.1 The therapeutic efficacy testing approaches 
This brief introductory section will attempt to briefly address the possible approaches to 
establish what was discussed above in the introduction of this thesis on cancer and 
frankincense. ‘The development of therapeutics for the clinical management of cancer is 
traditionally defined in several distinct phases, including discovery, in vitro testing, pre-
clinical animal studies, and clinical trials’(Gordon, Brown and Reynolds, 2018). A number of 
cell-based approaches to determine the therapeutic efficacy were discussed by Gordon et al. 
(2018). The approaches can be divided into categories as follows. Cell viability and 
proliferation assays by measuring cell activity through metabolic activity or colony formation 
assays to evaluate tumour progression in vitro as examples. The second category is 
cytotoxicity assays which can be achieved by staining and imaging, propidium iodide as an 
example, or lactate dehydrogenase (LDH) release assay. Cell apoptosis assays are the third 
category that involves DNA fragmentation assays, caspase activation and flow cytometry for 
the caspases or alive/dead cells stains such as Annexin V and propidium iodide. Finally, cell 
cycle arrest assays are another approach where the efficacy of anti-tumour agents is tested. 
Determination of cellular viability and the morphological changes on the ovarian cancer cells, 
in vitro, that could result from exposing them to the candidate extracts and agents serves as 
an essential starting point of this project. The 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) dye reduction assay was used to assess cellular viability 
based on metabolic activity. The following chapters will include cell cycle analysis and 
investigations of possible molecular targets of the agents. 
 
2.1.2 In vitro models of human ovarian cancer 
Considering the above, ovarian cancer has been shown to be complex and distinct with 
multiple sub-types based on histological and pathological categorisation. The multiplicity is 
also apparent on molecular levels. It is then critical to utilise appropriate in vitro models in 
pre-clinical studies. The publicly available ovarian cancer cell lines are about 100 with 
various cellular and molecular features (Beaufort et al., 2014). Since EOC cancer represents 
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90 % of all ovarian cancers (Gloss and Samimi, 2014), it is justifiable to consider using EOC 
in vitro models in this project which will be mentioned below (see 2.1.2.1 an 2.1.2.2). 
 
2.1.2.1 A2780, A2780cis and A2780ADR 
A2780 is an epithelial ovarian cancer cell line that was derived from an ovarian endometroid 
adenocarcinoma tumour in an untreated patient (Public Health England, 2016). A2780 is one 
of the most commonly used in vitro models of ovarian cancers which accounts for 60 % of 
the publications with SK-OV-3 cell line. In recent years, the use of A2780 as model of 
HGSOC is being questioned due to the lack of the key genomic characteristic of HGSOC 
which include TP53 mutations and substantial copy-number changes (Anglesio et al., 2013; 
Domcke et al., 2013; Bourgeois et al., 2015; Tudrej et al., 2018). It is also mentioned that 
A2780 is most likely part of an endometroid histological sub-type (Beaufort et al., 2014). 
In an attempt to understand the mechanisms of chemoresistance in ovarian cancer and to 
investigate possible approaches to overcome it, researchers developed resistant variants of 
A2780 called A2780cis and A2780ADR. The resistance to cisplatin, A2780cis, and to 
doxorubicin, A2780ADR, was induced by the chronic exposure of the parent A2780 cell line 
to the chemotherapies (Behrens et al., 1987; Public Health England, 2013b, 2013a). These 
developed variants serve as a crucial tool in cancer research. 
 
2.1.2.2 OVCAR4 
Taking into account the potential lack of resemblance of A2780 to HGSOC, the cytotoxicity 
of various treatment approaches were also examined on OVCAR4. OVCAR4 shares with 
A2780 the fact that the histological subtype was not attributed by the originator. However, 
OVCAR4 is widely accepted as a model of HGSOC based on its genomic features (Domcke 
et al., 2013). In addition to the mutation in TP53, Bourgeois et al. (2015) demonstrate a 
number of molecular features that OVCAR4 shares with ovarian tumours such as the 
expression of matrix-metalloproteinase-2 (MMP2) which is found to be increased in ascites 
fluid in advanced stage ovarian cancer and is associated with the ability of tumour to invade 
surrounding tissues. OVCAR4 was derived from patient who was previously treated with 
cyclophosphamide, cisplatin and doxorubicin and became resistant to the treatment (Louie et 
al., 1985).  
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Considering the above discussed details on the cell lines, A2780 is an appropriate candidate 
model as sensitive cell line without previous history of exposures to the tested agents and the 
possible development of and comparison to the resistant variants, A2780cis and A2780ADR. 
In addition, OVCAR4 is another superior model to confirm the effects of the tested agents on 
ovarian cancer due to the discussed higher relativity to ovarian cancer in patients. 
 
2.1.2.3 Cell culture limitations 
Researchers use patient biopsies, genetically engineered mouse models, patient-derived 
xenografts, patient stem cell-derived organoids and/or cancer cell lines to study human cancer 
cell biology. Despite the acknowledged lack of human biology recapitulation, cell lines 
remain the most commonly used system for being practical and relatively easy to handle 
(Hynds et al., 2018). A human cancer cell line only represents a snapshot of a tumorigenic 
process, which consists of multiple stages in humans, and a single type of cells whereas 
tumour microenvironment consists of various cell types (Hynds et al., 2018). The other key 
limitation of cancer cell culture is heterogeneity and genetic instability, where cells continue 
to evolve in culture leading, perhaps, to discrepancy in the results (Ben-David et al., 2018). 
The heterogeneity may, however, be used as an advantage (Hynds et al., 2018) since genomic 
instability is one of the hallmarks of cancer (Hanahan and Weinberg, 2000, 2011).  
Other differences are related to in vivo and in vitro culture conditions, where in vivo 
conditions are physiologically controlled and in vitro conditions are artificially optimised. 
The concentration of serum, for instance, in solid tumours is less than 1 %, while the 
concentration range in cell culture is 3-10 % (Staveren et al., 2009). Moreover, the 
atmospheric oxygen concentration in standard cell culture incubators is about 20 % compared 
to 2-9 % physiological level in tissues, which is even lower in tumours (Bertout, et al., 2008; 
Staveren et al., 2009; Geraghty et al., 2014). It is noteworthy to mention that the high 
atmospheric oxygen level does not necessary reflect the pericellular concentration of oxygen. 
The condition may vary from hyperoxia to near-anoxic due to oxygen's inert diffusion rate 
through aqueous medium, which is affected by cell density, media volume and barometric 
pressure (Place, Domann and Case, 2017). 
This brief overview covered some of the differences between in vivo and human cancer cell 
culture and indicate to the importance of monitoring culture conditions in order to increase 
data reproducibility and reliability. It is, as well, crucial to continue to develop cell culture 
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models to improve their relevance to human tumours. Cancer cell lines are still one of the 
most useful experimental systems in modern cancer research and shares the following 
hallmarks of cancer with cancer cells in vivo: self-sufficiency in growth control, insensitivity 
to antigrowth signals, escape from checkpoints, immortality, genetic instability, loss of 
negative feedbacks and invasiveness (Staveren et al., 2009; Place, Domann and Case, 2017). 
Finally, the discussed points should be taken into consideration when interpreting results on 
cell culture and more importantly data should not be extrapolated to in vivo models without 
proper testing.  
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2.2 Materials and Methods 
2.2.1 Materials 
All materials were obtained from Thermo Fisher Scientific (Loughborough, UK) or Sigma-
Aldrich via SLS (Huddersfield, UK), unless noted otherwise. 
- RPMI-1640 medium 
- Phosphate buffered saline (PBS) 
- Newborn calf serum (NCS) 
- Dimethyl sulfoxide (DMSO) 
- Trypsin-EDTA (Ethylenediaminetetraacetic Acid) 
- Ethanol 
- Trypan blue 
- Cell culture plastic wares 
- 96-well microplate 
- MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) 
- Haemocytometer (cell count chamber) 
- Freezing box 
 
2.2.2 Compounds and drugs 
3-Acetyl-11-keto-β-boswellic acid (AKBA, solvent: DMSO), Cisplatin (cis-
Diamineplatinum(II) dichloride, solvent: PBS), doxorubicin hydrochloride (solvent: DMSO) 
and Paclitaxel (solvent: DMSO) were purchased from Sigma-Aldrich (St Louis, MO, USA).  
PBS was used to dissolve cisplatin due to the structural and functional changes that could 
arise from dissolving platinum based compounds using DMSO (Hall et al., 2014). AKBA 
was also supplied by Dr A. Al-Harrasi, University of Nizwa, Oman, which was only used in 
the beginning of this project on A2780 for MTT assay. The difference in EC50 was negligible 





2.2.3 Cell lines and culture 
The A2780 cell line is derived from an ovarian endometroid adenocarcinoma tumour in an 
untreated patient, the cisplatin resistant counterpart A2780cis and the doxorubicin resistant 
counterpart A2780ADR were purchased from Sigma-Aldrich (St Louis, MO, USA). The 
vials of cells contained 1 mL of cells and were frozen in liquid nitrogen. To revive, cells were 
thawed at 37 °C, transferred from a cryovial to a 15 mL screw cap, conical polypropylene 
tube and 9 mL RPMI-1640 medium, plus GlutaMAXTM (2 mM) and 10 % v/v NCS washed 
with RPMI-1640 medium and then PBS, and transferred to fresh medium in a T75 (surface is 
75 cm2) flask to be cultured and maintained. After 24 hours, medium was replaced with fresh 
medium. Cells were maintained in RPMI-1640, plus 2 mM GlutaMAXTM and 10 % v/v NCS 
at 37 °C in a humidified atmosphere of 5 % CO2 to be sub cultured every 48 hours, when the 
confluence was between 70 and 80 %. In addition, 1 µM cisplatin was added to the A2780cis 
cell line and 100 nM doxorubicin to the A2780ADR cell line every two to three sub-cultures 
to maintain resistance. It is noteworthy to mention that a passage number limit was 
introduced based on the observed change in the growth rate for each cell line. For example, 
A2780 cells were used in experiments between revival (passage 13) and passage 30, where 
changes in the growth pattern usually happen. Similar range was applied for A2780cis and 
A2780ADR, while the range was between passages 14 and 18 for OVCAR4.  
The other cell line used in this project was OVCAR4 cell line that was a kind gift from 
Professor Iain McNeish, Beatson Institute of Cancer Sciences, University of Glasgow, UK. 
OVCAR4 cells were originally obtained from Dr R. Camalier, Developmental Therapeutics 
Program, National Cancer Institute MD, USA. OVCAR4 is a high grade serous 
adenocarcinoma from ovarian epithelium which was derived from a patient resistant to 
platinum-based chemotherapy (Lengyel et al., 2014). The Following conditions were 
followed to grow and maintain OVCAR4 cells: growth medium was DMEM (Dulbecco's 
Modified Eagle Medium) + 2 mM GlutaMAXTM + 4.5 g/L D-glucose + 110 mg/L pyruvate 
and incubated at 37 °C in a humidified atmosphere of 5 % CO2. 
To sub culture and seed, the medium was removed and cells washed with PBS at 70-80 % 
confluency, which then followed by trypsinisation, trypsin-EDTA was used to detach cells 
from the surface. The split ratio of sub cultured cells was between 1:2 and 1:6 following the 
provider’s recommendation, which entirely depended on cell proliferation. The effect of 
trypsin-EDTA was neutralised using culture medium plus NCS. Enough volume of fresh 
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medium was added to the newly seeded cells to be incubated for further uses. For example, 6 
to 9 mL of fresh medium is added to a T25 flask that will be incubated for 48 to 72 h before 
the next sub culture. 
To freeze vials of the cells, cells were sub-cultured in T75 flasks to produce sufficient 
numbers of cells for freezing, e.g. 10 flasks with cells at 80 % confluence gave approximately 
100 million cells in total of A2780 cells. Detached cells were combined and pelleted at 400 
xg, 4 minutes in a centrifuge and a suitable volume of freezing medium (RPMI-1640 + 2mM 
Glutamine + 10% v/v NCS + 8 % v/v DMSO) was added to the pellet to give a cell density of 
3.5 x 106 cells per mL. Aliquots of 1 mL of this suspension was divided to an appropriate 
number of cryovials. The vials were transferred to a freezing container and kept at – 80 °C 
overnight, then transferred to liquid nitrogen for longer term storage. 
 
2.2.4 Seeding and treatment 
In order to seed cells for treatment, cells were counted in a haemocytometer to determine the 
approximate density of the cell suspension following trypsinisation, this was then used to 
calculate the volume of cells to be added to the wells of a sterile 96 well plate to get the 
appropriate starting density per well (see section: 2.3.1). Cells were seeded in a 96-well 
microplate and then incubated for 24 hours to adhere to the plate, grow and recover from the 
seeding. After 24 hours cells were treated with various concentrations of the desired 
compound for 24 hours to be used in cytotoxicity assays (see below). A number of attempts 
were required to reach an optimal concentration range to establish the EC50 of a compound 
that had not been well investigated. For instance, various concentrations of paclitaxel were 
used starting from a very low concentration to a very high concentration, wide dose ranges 
which were then used to refine the dose range for determining EC50. 
The combination of AKBA with tested drugs was performed as follows: cells were treated 
with 26 µM of AKBA (See section: 2.3.3), which was lower than the EC50 of AKBA on all 
cell lines, and various concentrations of the agent simultaneously for 24 hours. The effect of 
the combination on cells was measured using a viability assay (see below). 
The other approach of treatment was as follow. Cells were pre-exposed to 26 µM AKBA 
alone for 24 hours. Then, AKBA was removed and replaced with a fresh medium and various 
concentrations of doxorubicin. Finally, MTT assay was performed. This approach for some 
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exposure experiments was taken to examine if the effect of AKBA, for example gene 
expression, signalling or metabolic effects, persisted after the AKBA had been removed. 
 
2.2.5 Frankincense extraction 
5.2 g of Omani frankincense resin (al hojary grade) was ground to a fine powder using a 
pestle and mortar. 4.95 g of the fine powder was transferred to a fresh tube, where 20 mL of 
70 % v/v ethanol in water was added. The slurry was left on an orbital shaker overnight.  
Then, the mixture was centrifuged at high speed to remove particles. The resultant material 
comprised of three layers: precipitated particles (at the bottom), oily phase (in the middle) 
and clear liquid phase (at the top). The oily and clear phases were transferred together to a 
fresh 15 mL screw top polypropylene tube and then were centrifuged again to remove any 
remaining particles. The two layers were separately transferred to two clean 50 mL round 
bottomed flasks and the solvent was removed using a rotary evaporator with water bath set at 
50 °C. Residual water was removed by freeze drying for 7- 8 h until the weight of the flask 
stabilised. The dry extracts were stored at -20 °C until further use.  Solvent-free extracts were 
reconstituted in DMSO. 
To mimic the traditional use of the frankincense resin, two pieces of roughly equivalent size 
resin were put in distilled water for 24 hours. A similar procedure to that was used for the 70 
% v/v ethanol extracts was applied to the water extract (only freeze drying was used) 
excluding dissolving the dried product in DMSO. The final dry product was dissolved in 
sterile PBS and filter sterilised using a 0.22 µm syringe filter. 
 
2.2.6 Cell viability assay 
Cell growth/viability was determined by the 3-(4,5-dimethylthiazol- 2-yl)-2,5-
diphenyltetrazolium bromide (MTT) dye reduction assay. The principal mechanism of the 
assay relies on the production of intracellular purple formazan by metabolically active cells 
as a metabolic product of reduced tetrazolium salts, which can be then solubilised and 
quantified using spectrophotometer. The treatment medium from the treatment (see above) 
was replaced with 200 µL fresh medium. A final concentration of 0.5 mg/mL of MTT 
solution (stock solution: 5 mg/mL MTT in PBS) was added to the cells in fresh medium and 
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incubated for 2 hours at 37 °C in a humidified atmosphere of 5 % CO2. Medium with MTT 
was removed and crystals then dissolved using 150 µL DMSO, which was then incubated for 
15 minutes at 37 °C in 5 % CO2. An inverted light microscope was used to confirm that 
crystals were totally dissolved. The absorbance was measured using a microtitre plate reader 
(GloMax® Discover System, GM3000, Promega Corporation, USA) at 600 nm. Data are 
presented as graphs showing the mean and SEM plots of three independent experiments (See 
section: 2.2.8). 
To determine the optimal number of cells for seeding for MTT assay (for subsequent viability 
assay), various numbers of cells were initially added per well, covering the range 10,000 to 
80,000 cells per well. Cells were incubated for 48 hours, medium was replaced with fresh 
medium after the first 24 hours. The optical density was read on the microtiter plate reader at 
a wavelength of 600 nm. The optimal cellular seeding number was determined using the data 
from three independent experiments. Graphs were plotted using Microsoft Excel (for Mac, 
version 15.28). The optimal seeding density was determined based on a seeding density that 
gave a final absorbance reading of 0.75 - 1.25 (American Type Culture Collection, 2011). 
 
2.2.7 Isobolographic analysis 
The interaction between AKBA and each one of the selected chemotherapeutic drugs, 
cisplatin, doxorubicin or paclitaxel, was evaluated by treating cells with different 
concentrations of one drug in the presence or absence of AKBA. The EC50 was determined 
by plotting data of three independent experiments. The combination index (CI) was used to 
determine the interaction by applying the following formula: 




($&1 × $&2) 
where $-1 is dose of drug 1 to produce 50 percent cell viability alone; $1 is dose of drug 1 
to produce 50 percent cell viability in combination with $2; $-2 is dose of drug 2 to produce 
50 percent cell viability alone; $2 is dose of drug 2 to produce 50 percent cell viability in 
combination with $1 (Chou and Talalay, 1983; Hossain et al., 2012; Khan et al., 2014). 
 
 47 
2.2.8 Statistical analysis 
The EC50 was determined using nonlinear regression (curve fit) on GraphPad Prism (version 
7.0b for Mac OS X, GraphPad Software, La Jolla California USA, www.graphpad.com). 
Results are shown as mean ± SEM. Since the mean of the means of each dose of 3 
independent experiments is shown, SEM was chosen to show the difference between the 
means and how precise the means are (Hertzog, 2017). Unpaired t-tests using GraphPad 
Prism (version 7.0b for Mac OS X, GraphPad Software, La Jolla California USA, 
www.graphpad.com) were used to assess if the difference between the effect of each 
compound on the examined cell lines was statistically significant. This was also applied to 
test the significance of the difference between the level of cytotoxicity of the investigated 
compounds and the effect of the combination by comparing the EC50 values or the viability of 
the cells on every single dose. The difference was considered statistically different, if P<0.05.  
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2.3 Results 
2.3.1 Experiment optimisation 
2.3.1.1 Optimal cell seeding number for MTT assay 
As an example, the optimal seeding number for A2780 lies between 25,000 and 35,000 cells 
per well at the wavelength of 600 nm (Figure 2.1). However, in subsequent experiments it 
was noted that the optimal seeding number depends on the growth rate of the cells 
proliferating prior to seeding. For example, 20,000 cells per well is the optimal density if 
A2780 cell count is more than 3 million cells/mL when the contents of a T25 flask are 
harvested, so seeding number was adjusted accordingly. Optimal seeding number for other 







Figure 2.1: Optimal cell seeding number for MTT assay of A2780 at 600 nm. Data are shown as mean 
± SEM for n= 3 independent experiments. 
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2.3.1.2 Assessing DMSO toxicity 
The other part of optimisation considered the percentage of DMSO per well. A broad range 
of DMSO percentages was used to deliver various concentrations of dissolved AKBA, 
doxorubicin or paclitaxel to the cells. The highest percentage of DMSO in a well was 0.74 % 
v/v in medium. A concentration of 0.8 % v/v DMSO in medium was monitored regularly to 
confirm that DMSO was not affecting the viability of the cells. For example, the viability of 
A2780 cells exposed to 0.8 % v/v DMSO in medium was 97 ± 2 % (n=3) of the negative 
control. The difference between the viability of negative (untreated cells) control and cells 
exposed to DMSO was not statistically significant (P=0.17). 
 
2.3.2 In vitro cytotoxicity assay 
2.3.2.1 The level of cytotoxicity of the tested agents individually on the selected cell lines 
The cytotoxicity of AKBA, cisplatin, doxorubicin, paclitaxel and the two parts of 70 % v/v 
ethanol frankincense extract (clear, FEc, and oily, FEo) on all or some of the selected cell 
lines, A2780, A2780cis, A2780ADR and OVCAR4, was assessed in vitro using the MTT 
assay. A cell line is considered as a resistant cell line if the EC50 of resistant cells/EC50 of 
parental cell is more than 2, called resistance factor (Vallo et al., 2015). The EC50 values for 
AKBA, cisplatin, doxorubicin, paclitaxel, FEc and FEo on A2780 were 30.76 ± 1.71 µM, 
12.36 ± 2.15 µM, 1.96 ± 0.33 µM, 80 ± 9.5 nM, 14 ± 2 µg/mL and 30.46 ± 2.3 µg/mL, 
respectively (Figure 2.2).  
A2780cis was resistant to cisplatin as the EC50 value was 38.62 ± 7.3 µM, where the 
resistance factor (RF) is 3.12. In contrast, A2780cis cells were as sensitive to AKBA (EC50 
35.64 ± 0.78 µM), doxorubicin (0.97 ± 0.19 µM), paclitaxel (7 ± 1.46 nM) , FEc (11.5 ± 3 
µg/mL) and FEo (32 ± 5.5 µg/mL) as A2780 (Figure 2.3). The difference between the effect 
of AKBA on A2780 and A2780cis was not statistically significant (P>0.05), whereas the 
difference between the EC50 of both cisplatin and doxorubicin on A2780 and A2780cis was 
statistically significant (P<0.05). 
The EC50 value of doxorubicin on A2780ADR (49 ± 5 µM, RF = 25) shows how resistant the 
cell line was to doxorubicin compared to its sensitive parent, A2780. Additionally, the EC50 
value of AKBA on A2780ADR was 30 ± 2 µM, which is similar to EC50 on A2780 (Figure 
2.4). The difference between the EC50 of doxorubicin on A2780ADR compared to its EC50s 
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on A2780 A2780cis and OVCAR4 was statistically significant (P<0.0001), while the EC50 of 
AKBA on A2780ADR was not significantly different to the other cell lines. 
The tested candidate agents were also toxic to OVCAR4 with the following EC50 values 40 ± 
4 µM for AKBA, 8 ± 2 µM for cisplatin and 2.4 ± 0.3 µM for doxorubicin (Figure 2.5). The 
difference between the EC50 of cisplatin or doxorubicin on OVCAR4 compared to the other 
cell lines was only statistically significant once compared to the resistant cell lines that are 





 Figure 2.2:  Cytotoxicity of AKBA, cisplatin, doxorubicin, paclitaxel and both the clear and oily components of the 70 % v/v 






Figure 2.3: Cytotoxicity of AKBA, cisplatin, doxorubicin, paclitaxel and both the clear and oily components of the 70 % v/v ethanol 
frankincense extract on A2780cis cells. The mean ± SEM of at least n = 3 independent experiments is shown. 



























Figure 2.5:  Cytotoxicity of AKBA, cisplatin and doxorubicin on OVCAR4 cells. The mean ± SEM of at least n = 3 independent experiments 
is shown. 















EC50= 2.4 ± 0.3 µM
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2.3.3 The interaction of AKBA with tested chemotherapies 
2.3.3.1 Cisplatin with AKBA 
The results of treating A2780 cell line with various concentrations of cisplatin and 26 µM of 
AKBA simultaneously for 24 hours in three independent experiments indicated that there was 
antagonistic effect between AKBA and cisplatin at doses higher than the EC50 of cisplatin on 
A2780 as shown in the graph (Figure 2.6) and confirmed after calculating the CI value (Table 
2.1). Data on A2780cis confirms the antagonism between AKBA and cisplatin including the 
low doses of cisplatin (Figure 2.6 and Table 2.1). The EC50 of both methods of treatment was 
not statistically different from the EC50 of cisplatin alone (P>0.05). Comparing the EC50 
simply does not reflect the apparent negative effect of the presence of AKBA with cisplatin at 
doses above the EC50. Therefore, another statistical approach was applied by comparing 
single doses of cisplatin in the presence and absence of AKBA. This revealed that the 
antagonistic effect of AKBA on cisplatin on both cell lines was statistically significant when 
cisplatin dose is more than the EC50. Finally, moderate antagonism was found between 
AKBA and cisplatin on OVCAR4 (CI=1.3) even though the EC50 was, to some degree, 
improved, where the EC50 was halved in the presence of AKBA compared to the EC50 when 
cells were exposed to cisplatin alone (Figure 2.6). Despite the CI value, the interaction 
between AKBA and cisplatin on OVCAR4 is negligible. 
2.3.3.2 Doxorubicin-AKBA interaction 
The interaction between doxorubicin and AKBA was assessed by treating cells with various 
concentrations of doxorubicin and 26 µM of AKBA simultaneously for 24 hours. The EC50 
of the combination was 29, 23, 25 and 16 fold less than the EC50 of treating cells with 
doxorubicin alone on A2780, A2780cis, A2780ADR and OVCAR4 cells, respectively 
(Figure 2.7). There was a synergistic effect between AKBA and doxorubicin on A2780, 
A2780cis, A2780ADR (pre-exposed to AKBA) and OVCAR4 and an additive action on 
A2780ADR (AKBA added simultaneously with doxorubicin) (Table 2.1). These effects were 
statistically significant (P<0.05). 
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Table 2.1: Combination index (CI) results from isobolographic analysis 
Treatment                                            CI 





Cisplatin + AKBA 3 3.2 1.3 - 
Doxorubicin + AKBA 0.9 0.81 0.75 0.94/pre-exposure 0.87 
Paclitaxel + AKBA 1.09 1.36 - - 
CI = or greater than 1.3: antagonism; CI = 1.1– 1.3: moderate antagonism; CI = 0.91–1.1: 
additive effect; CI = 0.81–0.9: slight synergism; CI = 0.61–0.8: moderate synergism; CI = 
0.41–0.6: synergism; and CI = 0.2– 0.4: strong synergism. Data represents the mean of 





Figure 2.6: Cytotoxicity of cisplatin on A2780, A2780cis and OVCAR4 cell lines treated with and without AKBA. Cells were treated with 26 
µM AKBA and various concentrations of cisplatin for 24 hours simultaneously to test the synergism between these compounds (blue). Cells 








2.3.3.3 Paclitaxel with AKBA 
Paclitaxel was used alone and in the presence of 26 µM AKBA on A2780 and A2780cis 
cells. The EC50 was slightly lower on both cell lines when the cells were exposed to both 
paclitaxel and AKBA (Figure 2.8). However, the CI value showed that there was additive 





Figure 2.7: Cytotoxicity of doxorubicin on A2780, A2780cis, A2780ADR and OVCAR4 cell lines treated with and without AKBA. Cells 
were treated with 26 µM AKBA and various concentrations of doxorubicin for 24 hours simultaneously to test the synergism between these 






Figure 2.8: Cytotoxicity of paclitaxel on A2780 and A2780cis cell lines treated with and without AKBA. Cells were treated with 26 µM AKBA and 
various concentrations of paclitaxel for 24 hours simultaneously to test the synergism between these compounds (blue). Cells were treated with 




2.3.3.4 Modulation doxorubicin cytotoxicity by pre-exposure of A2780 cells to AKBA 
A2780ADR cells were exposed to 26 µM of AKBA for 24 h then the medium was replaced 
with fresh medium containing various concentrations of doxorubicin and cells exposed to 
doxorubicin for 24 h. The reason for using this approach was to examine that the apparent 
synergism between AKBA and doxorubicin is more likely due to AKBA-induced cellular 
changes rather than a physiochemical interaction between the two compounds. The control 
set of cells were allowed to grow without doxorubicin for 24 h while the others were being 
treated with AKBA. Doxorubicin was then added to both sets of cells. The EC50 of 
doxorubicin was remarkably lowered after pre-exposing cells to AKBA for 24 h where it was 
reduced from 104 ± 6 µM in the cells treated with doxorubicin alone to 0.7 ± 1 µM in the 








Ovarian cancer is one of the leading causes of death among women cancers in the west 
(Jayson et al., 2014). It is a difficult disease to treat for the reasons mentioned in the 
introduction such as the heterogeneity and the insufficiency of adequate diagnostic 
approaches in the early stages of the disease. The main approach to treat ovarian cancer 
involves chemotherapeutic agent regimens in addition to surgery. Chemotherapies cause a 
number of unpleasant and in some cases serious complications. Therefore, developing new 
agents to either treat, increase the efficacy of conventional chemotherapies at low doses or 
reduce the side effects of them is required. Plants were one of the natural sources of 
therapeutic agents thorough the history of developing medicinal agents. One of the plants 
used in traditional medicine against various diseases is frankincense (from Boswellia sp.). 
The possible effects of AKBA, a biologically active compound from frankincense, and 
extracts of frankincense using ethanol or water on ovarian cancer in vitro models and on 
conventional chemotherapies efficacy was explored in this project. 
 
2.3.4.1 AKBA and frankincense extracts toxicity on ovarian cancer models 
The ability of AKBA to effectively reduce the viability of ovarian cancer cells in vitro is 
shown using various cell lines, A2780, A2780cis, A2780ADR and OVCAR4. This confirms 
the results of previously unpublished work by K. Al Salmani et al., who studied the effects of 
AKBA on ovarian cancer in vitro, for the first time using a number of ovarian cancer cell 
lines. In addition, the results in the current study has established the cytotoxicity of the 70 % 
ethanol extract of the resin towards A2780 and its resistant counterpart A2780cis (Figure 2.2 
and 2.3). This could be a result of the presence of AKBA in the extract as shown using TLC 
(see appendix), which needs further confirmation and quantification using HPLC, for 
example. 
In contrast, the water extract, to mimic one of the traditional ways in the preparation of the 
resin to treat diseases, was not toxic towards A2780 cell line. This could be investigated 
further by changing or adapting the extraction method. For example, frankincense essential 
oils extracted by hydrodistillation of Boswellia sacra gum resins was reported to be toxic 
towards breast and pancreatic cancers (Suhail et al., 2011; Ni et al., 2012). 
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2.3.4.2 Potential antagonism of cisplatin toxicity by AKBA 
Potential antagonism between AKBA and cisplatin was observed in the isobologram results 
and confirmed statistically on a number of doses. This might occur due to physiochemical 
interaction between the compounds when they are present simultaneously resulting in loss of 
activity of cisplatin. It is important to note that the reduction in the toxicity of cisplatin due to 
the presence of AKBA occurs at doses higher than the EC50 of cisplatin on both A2780 and 
A2780cis but not on OVCAR4. The other possible reason for the reported antagonism is 
cytoprotection of cells that could result from induced Nrf2 induction. AKBA neuroprotection 
was attributed to the increased expression of Nrf2 (Ding et al., 2014). Nrf2 over-expression 
has been reported to be a contributor to resistance of cells to cisplatin (Wang et al., 2008) and 
its inhibition sensitised resistant ovarian cells to cisplatin (Cho et al., 2008; Ji et al., 2013). 
The role of Nrf2 in this phenomenon will be examined in the later chapters. 
 
2.3.4.3 Improving the toxicity of doxorubicin by AKBA 
Taking into account the CI values, synergistic (on A2780, A2780cis, OVCAR4 and pre-
exposed A2780ADR) and additive (on A2780ADR) effects were observed after treating cells 
with a combination of AKBA and doxorubicin for 24 h. The toxicity of doxorubicin towards 
all tested cell lines was remarkably increased as a result of the presence of AKBA (26 µM). 
Moreover, AKBA sensitised the doxorubicin resistant cell line, A2780ADR, to doxorubicin. 
Khan et al. (2014) stated a synergistic effect of BSE in combination with doxorubicin against 
hepatocellular carcinoma. The synergistic interaction between AKBA and doxorubicin could 
be attributed to molecular changes following the exposure of the cells to the agents together. 
Cells were pre-exposed to AKBA for 24 h before adding a fresh medium and doxorubicin in 
an attempt to understand if the interaction is taking place on a molecular level or is a 
physiochemical reaction between the agents. The data (Figure 2.9) imply that the interaction 
is on a molecular level, since the EC50 of doxorubicin on A2780ADR was 100 fold less than 
the cells that were treated with doxorubicin but not pre-exposed to AKBA, whereas the 
difference between the EC50s when the agents were added simultaneously compared to 
doxorubicin alone was approximately 25 fold. The synergistic interaction between AKBA 
and doxorubicin is a promising indicator that AKBA could be used as an adjuvant and 
doxorubicin doses could be reduced which then may lead to less side effect of the agent. 
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Other points worth highlighting are the toxicity of the dose of AKBA (26 µM) and the 
doubled EC50 value of A2780ADR in pre-exposure experiments. The cell viability of cell 
lines treated with 26 µM AKBA lies between 60 and 70 %. This may suggest that the 
improvement is due to the additive cytotoxicity of AKBA and doxorubicin together, not the 
synergistic interaction between the agents, which is at least of benefit. However, the CI 
values indicate a synergistic interaction between AKBA and doxorubicin. Moreover, there 
was antagonistic interaction between AKBA (26 µM) and cisplatin despite the toxicity of 
AKBA. In addition, the increased EC50 value of doxorubicin on A2780ADR could be 
attributed to background noise. The other proposed reason is the time that was given to cells 
to grow in the plate before exposing them to doxorubicin, which is 24 h more as described in 
section 2.2.4. 
A number of molecular targets and cellular mechanisms could be involved in the synergistic 
interaction between AKBA and doxorubicin. For instance, both AKBA and doxorubicin were 
reported to induce cell cycle arrest at G1 and G2/M phase, respectively, as one of the 
mechanisms to trigger cell death in cancer cells (Liu, Huang and Hooi, 2006; Kim, Lee and 
Kim, 2009). Exploring such processes and targets could help reveal the molecular 
mechanisms behind the synergistic interaction. The effects of AKBA and doxorubicin on cell 
cycle, the mitochondria, NFκB pathway and P-gp protein expression will be investigated in 
the following chapters. 
 
2.3.4.4 Paclitaxel and AKBA between additive and antagonistic interactions 
Despite the increased toxicity of paclitaxel due to the presence of AKBA, the CI values 
indicate an additive effect on A2780 and slight antagonistic effect on A2780cis. This could 
be a consequence of the poor aqueous solubility of paclitaxel and lipophilic nature of both 
compounds (Rentea, 2008; Surapaneni, Das and Das, 2012). The exerted interaction of 
paclitaxel with AKBA resulted in the exclusion of it from further studies in this project. It lies 
between the synergistic interaction of doxorubicin and the antagonistic interaction of cisplatin 







Cell Cycle and Apoptosis  
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3 Cell cycle and apoptosis 
3.1 Introduction 
3.1.1 The cell cycle in normal and cancer cells 
Eukaryotic cells replicate by a process called the cell cycle, which consists of phases 
recognised as G1, S, G2 and M (Figure 3.1). When cell division is required, cells inter the 
cell cycle at G1 from G0, a resting (quiescent) phase where cells are not dividing, or continue 
in the cycle from M phase. The G1 and G2 are called gap phases, where a number of checks 
are conducted before entering either the S or M phases, respectively. The S, synthesis, phase 
is when DNA replication occurs and the M, mitosis, phase is when cells divide. Cell cycle 
progression is strictly controlled by multiple checkpoints to ensure the readiness of a cell to 
enter the cell cycle or move from one phase to another (Deraitus and Freeman, 2001). For 
example, DNA replication will be delayed or stopped if DNA damage is detected in the S or 
M phase, then DNA repair will take a place or the cell will be forced to go through apoptosis. 
The control system is mainly driven by cyclin-dependent kinases (CDKs) and their inhibitors. 
The CDKs regulatory subunit are cyclins as the name suggests. Active CDK-cyclin 
complexes in the cell cycle control the transition between the phases which is finetuned by 
regulatory phosphorylation or dephosphorylation (Collins, Jacks and Pavletich, 1997). 
 
Figure 3.1: Cell cycle phases. (Shutterstock ID: 1251867079) 
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Uncontrolled cellular proliferation and the lack of efficient checkpoints are parts of the 
hallmarks of cancer (Hanahan and Weinberg, 2000). Cell proliferation in cancer appears to be 
caused by the accumulation of genetic mutations that could induce uncontrolled cell growth, 
inhibit cell death and inactivate repair mechanisms (Vogelstein and Kinzler, 2004). Alteration 
in the cell cycle regulatory genes were sporadic across various types of ovarian cancer 
(D’Andrilli et al., 2004). The reported alterations involve overexpression of cyclins (A, B, 
D1, D2 and E), CdKs (2 and 4), Cdcs (2, 25A and 25B) and p21, and down-regulation of p16, 
Rb, Rb2/p130, p27 and p57, and mutation in p53, and homozygous deletion of p15 
(D’Andrilli et al., 2004). This variability could be related to the heterogeneity of the ovarian 
cancer and the complexity of the cell cycle mechanism. 
The therapeutic approaches to cancer, including ovarian, are developing towards more 
targeted therapies that target a specific gene, protein, pathway or mechanism. It is then 
rational to develop or investigate agents that target the cell cycle considering its crucial 
contribution to tumorigenesis. For example, aurora kinase inhibitors were reported to be 
effective against ovarian cancer in vitro and in vivo and, interestingly, an agent called 
MLN8054 is being examined in ‘the management of patients with platinum-refractory or 
resistant epithelial, fallopian, or primary peritoneal carcinoma’ (Campos and Ghosh, 2010). 
3.1.2 Cell death in normal and cancer cells 
In cell biology, there is more than one form of cell death, where variable mechanisms are 
involved. Controlled cell death is important in both physiological and pathological 
conditions. The established cell death types include, but are not limited to, apoptosis, 
necrosis, pyroptosis and autophagy, and the most recent discovered type is necroptosis 
(Figure 3.2) (Fink and Cookson, 2005; Dasgupta et al., 2017). This brief introductory section 
will focus on apoptosis and may include necrosis, as necessary, in both normal and cancer 






Figure 3.2: Cell death pathways in normal cells. Taken from (Fink and Cookson, 2005). 
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Apoptosis, the programmed cell death, is the most studied mechanism of cell death. It is a 
tightly controlled process that can occur during both physiological and pathological 
processes, which is the main feature that distinguishes apoptosis from necrosis, despite the 
recent indications that necrosis might also be a programmed cell death that occurs as a result 
of trauma or injury (Danial and Korsmeyer, 2004; Dasgupta et al., 2017). Apoptosis is one of 
the ways to maintain homeostasis within tissues during embryogenesis, aging and healing, for 
example. Cell shrinkage and nuclear condensation are among the characteristics that 
differentiate apoptosis from necrosis. The key players in apoptosis are caspases, proteolytic 
enzymes. Caspase-2, -8, -9 and -10 are known as the initiator caspases, which generally 
activate the executioner caspases that include caspase-3, -6 and -7 (Dasgupta et al., 2017). 
The apoptosis pathway can be divided into extrinsic and intrinsic pathway (Figure 3.3). The 
extrinsic pathway occurs as a response to extracellular stimuli of death receptor, which is also 
referred to as death receptor pathway. Cell death in this pathway happens as a result of the 
catalytic activity of caspases-8 and/or -10, which could be induced following a series of 
upstream multi-protein death inducing signalling. This starts from triggering cell surface 
death receptors by the binding to specific members of tumour necrosis factor (TNF) and, 
similar to the other pathways, ends in the catalytic activation of the executioner caspase-3 
(Ly, Grubb and Lawen, 2003; Elmore, 2007; Hotchkiss et al., 2009). The other examples of 




Figure 3.3: Extrinsic and intrinsic apoptosis. Created using Biorender. 
 
On the other hand, the intrinsic pathway, also known as mitochondrial pathway, is regulated 
by both pro- and anti-apoptotic members of the Bcl-2 protein family. This pathway is 
normally activated in a response to intracellular signals of cell damage such as increased 
levels of reactive oxygen species or DNA damage. The caspase playing a key role in the 
initiation of the intrinsic pathway in a response to the intracellular signals of the cell damage 
is caspase-9. Caspase-9 can also be triggered by cytochrome C released from disrupted 
mitochondria, which could initiate or result from apoptosis. Therefore, mitochondrial 
membrane permeability has been used as an indicator of the early stages of apoptosis or 
apoptosis in general (Ly, Grubb and Lawen, 2003; Dasgupta et al., 2017). There is ‘cross-
talk’ between the intrinsic and extrinsic apoptotic pathways, with caspases associated with 
one pathway activating caspases in the other. 
The importance of understanding apoptosis in cancer relies on the fact that evading apoptosis 










































































above, cell cycle arrest or the induction of apoptosis are the expected consequence of errors 
in cell cycle in healthy cells, which is impaired in most cases of tumourgenisis. 
Overexpression of pro-survival Bcl-2 was reported in about 50 % of human cancers, which 
may rseulted from oncogenes that dyregulate expression of this protein (Dasgupta et al., 
2017). The other example of the molecular causes of the defect of apoptosis in cancer is 
mutations in TP53, which intiate apoptosis in response to DNA damage, in a number of 
neoplasms including HGSOC (Hotchkiss et al., 2009). The induction of apoptosis in cancer 




3.2.1 Cell cycle analysis 
The effect of AKBA alone and combined with either cisplatin or doxorubicin on cell cycle 
phases was assessed on a flow cytometer by quantifying DNA staining. DNA contents were 
stained with propidium iodide (PI) after fixing cells with 70 % v/v cold ethanol. PI is a red-
florescent dye that can stain both DNA and RNA in either dead or permeabilised cells. Since 
the experiment is based on analysing DNA content, ribonuclease was used to remove RNA 
from tested samples. Four phases of cell cycle G1, S (DNA synthesis phase), G2 and M 
(mitosis phase) can be detected using this approach based on the brightness of the signal. The 
brighter the signal is the higher the DNA contents are. 
Cells were counted and seeded at the optimal cell density (5 x 105 cells per well in a 12-well 
plate) and allowed to attach for 24 h at 37 °C in 5 % CO2. The medium was replaced with 
fresh medium and various concentrations of AKBA, doxorubicin, cisplatin, AKBA (26 μM) 
combined with doxorubicin or AKBA (26 μM) combined with cisplatin were added. Two 
controls were included which are negative (untreated) and positive (etoposide). Cells were 
exposed to the tested agents for 24 h since the toxicity experiments were performed, mainly, 
at this time point. Moreover, the reported doubling time of A2780 cells is about 18 to 22 h 
(Beaufort et al., 2014). After 24 h, the medium was taken into fresh tube and the cells were 
trypsinised and combined with the supernatant from the same well. Cell suspensions were 
centrifuged at 600 x g for 5 minutes. The supernatant was removed and the cells were 
suspended in cold PBS as a wash, this was repeated once, cell were pelleted at 600 x g for 5 
minutes each time. Then, 70 % v/v ethanol in dH2O was used to fix the cells, by adding 
dropwise to the cells with gentle vortexing to allow single cell suspension formation. Fixed 
cells were then stored at -20 °C until PI staining and flow cytometry. For staining, fixed cells 
were washed twice with PBS, cells pelleted at 600 x g for 5 minutes. 500 μL of PBS was 
slowly added to the washed cells with gentle tapping. Then cells were treated with 
ribonuclease A (RNase A) (2.5 μL of 10 mg/mL) to ensure that DNA, not RNA, is stained. 
To stain the cells, 25 μL of 1 mg/mL PI was added to each tube. The tubes were incubated at 
37 °C for 30 minutes in the dark. Then, the tubes were placed on ice immediately and 
analysed by flow cytometry. Stained DNA was analysed/quantified using a BD Accuri C6 
Plus flow cytometer (BD Biosciences, USA). The resulted data was exported and then 
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analysed using FlowJo (V10, USA) (Figure 3.4). A total of 30,000 of events were acquired 




Figure 3.4: Example flow cytometry histogram showing different phases of the cell cycle. 
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3.2.2 Polarisation of the mitochondrial membrane 
JC-10 Mitochondrial Membrane Potential (MMP, Δψm) Assay Kit (ab11213, Abcam) was 
used to assess the effect of AKBA, cisplatin, doxorubicin and AKBA combined with either of 
the chemotherapies on mitochondria. JC-10 is a fluorescent cationic and lipophilic dye which 
aggregates in mitochondria if the mitochondria have an intact proton gradient (red 
fluorescence). In apoptotic and necrotic cells, the dye will diffuse out of mitochondria, 
forming green fluorescent staining. 
Cells were counted and seeded at 4 x 104 cells per well in a black 96-well microplate with 
clear bottom. Cells were allowed to attach and acclimatise for 24 h, 37 °C , 5 % CO2. The old 
medium was then removed and replaced with fresh phenol red free RPMI-1640 medium + 10 
% NCS. Cells were exposed to various concentrations of AKBA, doxorubicin, cisplatin or 
single dose of AKBA (26 μM) combined with either doxorubicin or cisplatin for 24h. To 
stain cells, the medium was replaced with PBS and the recommended volume of JC-10 
containing assay solution was added (see Appendix Δψm assay for protocol). The plate was 
incubated for 45 mins at 37 °C in 5 % CO2 before adding 50 μL of the assay buffer B. 
Finally, fluorescence intensity was monitored at excitation/emission (475/500-550 and 
520/580-640 nm) using a microtitre plate reader (GloMax® Discover System, GM3000, 
Promega Corporation, USA). These were the nearest values to the recommended ones: 
exitation/emission (490/525 and 540/590 nm). The ratio of 490/540 of each sample was 
calculated and then normalised to percentage against the negative control (untreated).  
 
3.2.3 Statistical analysis 
The statistical significance was tested using ordinary one-way ANOVA (Tukey multiple 
comparison statistical test) on GraphPad Prism 8. If P<0.05, the result was considered 
statistically significant. To compare the difference between single doses in the presence or 
absence of AKBA, unpaired t-tests using GraphPad Prism (version 7.0b for Mac OS X, 





3.3.1 Cell cycle 
3.3.1.1 The effect of AKBA on the cell cycle on A2780 
After treating cells for 24 h with AKBA, cell cycle arrest at G0/G1 was observed at the 
highest concentration of AKBA which was 62 µM (Figure 3.5). The difference to the control 
G0/G1 was statistically significant (P<0.0001). Moreover, the population at sub-G1 was 
considerably higher at the same concentration of AKBA (34 ± 9 % of the events) compared 
to untreated cells (4 ± 1 % of the events) and etoposide (5 µM, 13 ± 1 % of the events), 
topoisomerase inhibitor chemical, which was used as a positive control for the reported 
activity of the induction of cell cycle arrest at G2/M. This could be used as an indicator of the 
cell death caused by AKBA as it is a representative of the fragmented DNA (Table 3.1). The 
distribution of the cell cycle following the exposure of the cells to the other doses of AKBA 




Figure 3.5: Cell cycle distribution of A2780 exposed to AKBA for 24 h. The mean of 3 independent experiments ± SEM is shown. 
**** is P<0.0001 compared to control. 
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3.3.1.2 The effects of cisplatin alone or combined with AKBA on the cell cycle of A2780 cells 
Cells were also exposed to various concentrations of cisplatin for 24 h. Cell cycle was 
arrested at S phase at all tested concentrations 12, 15 and 23 µM (Figure 3.6). The difference 
to the control was statistically significant at both 12 and 23 µM doses. The percentage of the 
fragmented DNA at sub-G1 was elevated following treating A2780 cells with cisplatin for 24 
h. The percentages were 11, 29 and 38 % for 12, 15 and 23 µM, respectively (Table 3.1). 
In addition, cells were treated with 26 µM AKBA which was added simultaneously with 
cisplatin. Interestingly, the effect of cisplatin on S phase at 12 µM was significantly 
decreased and the cell cycle distribution was not significantly different to the control. The 
effect of the presence of AKBA with the other two doses was not statistically significant. 
Finally, the percentages of the events at sub-G1 of samples treated with cisplatin and AKBA 
were less than the ones treated with cisplatin alone at both doses 15 and 23 µM, which were 





Figure 3.6: Cell cycle distribution of A2780 exposed to cisplatin alone or combined with AKBA for 24 h. The mean of 3 independent 
experiments ± SEM is shown. *P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001 compared to control. The significant difference between 
the presence and absence of AKBA at 12 µM is shown in blue.   
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3.3.1.3 The effects of doxorubicin alone or combined with AKBA on the cell cycle on A2780 
The effect of doxorubicin on the cell cycle was assessed by exposing A2780 cells to 
doxorubicin or doxorubicin combined with AKBA for 24 h. Cell cycle arrest was reported at 
G2/M phase, which was statistically different to the control (Figure 3.7). Moreover, the 
percentages of the events at sub-G1, i.e. DNA fragments, were increased following the 
exposure to doxorubicin (Table 3.1). The presence of AKBA did not affect the changes to the 
cell cycle that caused by doxorubicin neither the percentages of the events at sub-G1. The 






   
 
 
Figure 3.7: Cell cycle distribution of A2780 exposed to doxorubicin alone or in combination with 26 uM AKBA  for 24 h. The 
mean of 3 independent experiments ± SEM is shown. *P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001 compared to control. 
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Table 3.1. The percentages of sub-G1 of A2780 cells exposed to various agents for 24h. 
Sample Dose (µM) Sub-G1 % SEM 
Control - 4 1 
Etoposide 5 13 1 
 
AKBA 
15 3 2 
31 1 0 
62 34 9 
 
Cisplatin 
12 11 3 
15 29 6 
23 38 14 
 
Cisplatin + 26 µM AKBA  
12 14 5 
15 18 8 





0.02 10 2 
0.07 16 5 
0.2 26 6 
0.7 30 7 
19 7 2 
 
 
Doxorubicin + 26 µM AKBA 
0.02 12 3 
0.07 14 4 
0.2 17 5 
0.7 24 4 




3.3.2 Mitochondrial Membrane Potential (MMP, Δψm) 
3.3.2.1 Single agent exposures and mitochondria depolarisation 
The effects of various treatment approaches on Δψm was assessed using JC-10 (fluorescent 
lipophilic dye). AKBA has significantly changed the Δψm at the highest concentrations (61 
and 72 µM) after exposing A2780 cells for 24 h. Mitochondrial depolarisation was also 
reported on the cells treated with cisplatin alone at 19 and 28 µM, which was significantly 
different to the untreated control. On the other hand, there was no significant change in the 






Figure 3.8: The effects of AKBA, cisplatin and doxorubicin on mitochondrial membrane potential on A2780. Cells were 
exposed to different concentrations of each tested compounds for 24 h. Data shown as the mean of  n=3 independent 
experiments ± SEM. *P<0.05 and  **P<0.01 compared to control. 
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3.3.2.2 Cisplatin or doxorubicin combined with AKBA on Δψm 
In an attempt to investigate the effect of combining AKBA with either cisplatin or 
doxorubicin on the changes to the Δψm that was caused by exposing A2780 cell to one of the 
agents alone, cells were treated with 26 µM AKBA combined with various concentrations of 
cisplatin or doxorubicin for 24 h. The impact of the presence of AKBA with cisplatin on the 
effect of the high concentrations of cisplatin on the Δψm was negligible and was not 
statistically different compared to the same doses without AKBA. On the other hand, there 
was a significant increase in the mitochondrial membrane depolarisation as a result of 




Figure 3.9: The effects of AKBA combination on the effects of cisplatin or doxorubicin on mitochondrial membrane 
potential on A2780. Cells were exposed to different concentrations of each tested compounds for 24 h combined with 
26.55 µM AKBA. Data shown as the mean of  n=3 independent experiments ± SEM. **P<0.01 compared to the control 
for the cells exposed to cisplatin. *P<0.05 and **P<0.01 compared to the same dose in the absence of AKBA for the 
cells exposed to doxorubicin. 
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3.4 Discussion 
3.4.1 The effect of AKBA, cisplatin and doxorubicin alone and in combination on cell cycle 
The cell cycle consists of four phases, G0/G1, S, G2 and M, and it is normally tightly 
regulated by a number of signalling pathways, checkpoints, kinases and other proteins. The 
impaired control of the cell cycle is one of key features of cancer. Targeting the cell cycle in 
cancer is one of the therapeutic approaches to either decelerate tumour growth or to induce 
cell death, either apoptosis or necrosis. The effects of tested agents, AKBA, cisplatin and 
doxorubicin, on the cell cycle were examined in this chapter.  
Cell cycle arrest at G1 was shown as a result of exposing A2780 cells to AKBA for 24 h. Liu, 
Huang and Hooi (2006) show that AKBA induced cell cycle arrest at G1 in colon cancer 
models, which was linked to the downregulation of G1 cyclins and CDKs by AKBA through 
p21 dependent pathway. The ability of AKBA to inhibit cellular proliferation could be, in 
part, a result of the induction of cell cycle arrest. The other noticeable effect is the amount of 
the fragmented DNA (sub-G1), which was considerably higher for the sample treated with 
AKBA compared to the control. This is reflective of cell death and another contributor to the 
inhibition of cellular growth (Chashoo et al., 2010; Lüpertz et al., 2010). 
Cisplatin induced cell cycle arrest at S phase, the DNA synthesis phase, with a reduction in 
the percentages of cells at G1 and G2/M phases. Cell cycle arrest at S phase after exposing 
HL-60, a human leukemic cell line, to low doses of cisplatin was reported by Velma, Dasari 
and Tchounwou (2016). They also show an accumulation of the cells at sub-G1 in a time 
dependent manner. In the current project, the increase of the signal at sub-G1 was dependent 
on the dose of cisplatin. 
The concurrent presence of AKBA with cisplatin interfered with the effect of cisplatin on cell 
cycle. The accumulated cells at S phase that was shown at 12 µM cisplatin was significantly 
decreased due to the presence of AKBA. AKBA also resulted in the reduction of fragmented 
DNA at sub-G1 when it was added with 15 and 23 µM cisplatin. These observations concur 
with the previous antagonistic interaction that was shown in the previous chapter (see 
2.2.2.1). 
The distribution of the cell cycle was significantly changed after exposing A2780 cells to 
doxorubicin for 24 h, where the cell cycle was arrested at G2/M phase. The percentages of 
the events at sub-G1 in the samples exposed to doxorubicin were higher than the control. 
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Lüpertz et al. (2010) state that doxorubicin induced cell cycle arrest at G2 (1 µM) and G0/G1 
(5 µM) in a dose and time dependent manner on a human colon carcinoma cell line, Hct-116, 
with an increase in the amount of fragmented DNA at sub-G1 with the lower dose of 
doxorubicin. Adding AKBA with doxorubicin did not lead to any changes to the effect of 
doxorubicin on the cell cycle, neither on the accumulated DNA fragments at sub-G1. 
 
3.4.2 The effect of AKBA, cisplatin and doxorubicin alone and in combination on Δψm  
Mitochondria are vital cellular organelles that are mainly responsible for ATP generation in 
eukaryotic cells. Mitochondria are key players in the intrinsic apoptotic pathway for the fact 
that the permeabilisation of its outer membrane leads to cytosolic release of proapoptotic 
proteins. The release of cytochrome c, for example, from the disrupted mitochondrial outer 
membrane to the cytoplasm can initiate apoptosis by inducing a conformational changes to 
apoptotic protease-activating factor-1 (APAF-1) protein which then bind to and activate 
caspase 9 to form a complex called apoptosome (cytochrome c, APAF-1 and caspase 9) 
(Dasgupta et al., 2017).  
Mitochondria have emerged as one of the targets for cancer treatments considering their role 
in cell survival and in apoptosis in both normal and pathological conditions. ‘Mitochondrial 
control of apoptosis has been described at several levels: (1) maintenance of ATP production 
and (2) Δψm and mitochondrial membrane permeability for the release of certain apoptogenic 
factors from the intermembrane space into the cytosol’ (Ly, Grubb and Lawen, 2003).  In this 
chapter, the changes to the Δψm following the exposure to tested agents and the combination 
approaches were explored. 
The impact of AKBA on the Δψm was significant at the high doses after exposing A2780 
cells for 24 h. Changes in the Δψm was observed by Lu et al. (2008) after exposing PC-3, a 
human prostate cancer cell line, to AKBA. Qurishi et al. (2012) reported a loss of Δψm in 
HL-60 cells that resulted from the exposure to 3- α -propionyloxy-β-boswellic acid (POBA), 
a synthetic derivative of β-boswellic acid. The loss of Δψm could be an indicator of the 
induction of apoptosis by creating pores and releasing proapoptotic proteins, such as 
cytochrome c, in the cytoplasm. 
Similar to AKBA, the Δψm was changed after exposing A2780 cells to cisplatin for 24 h. This 
observation complies with previously published data on the effect of cisplatin on the Δψm 
such as the one published by Xu et al. (2018) where changes in the Δψm was observed in 
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SKOV3 cells exposed to cisplatin. The depolarization of the mitochondria that was caused by 
cisplatin was not affected by the presence of AKBA. More repeats of the experiment, 
applying various experimental approaches and time points may lead to a more definitive 
conclusion. 
Finally, there were negligible changes in the Δψm towards the hyperpolarisation of the 
mitochondrial membrane following the exposure of A2780 cells to doxorubicin for 24 h. An 
opposite effect, that is mitochondrial membrane depolarisation, was noticed on a number of 
cancer cell lines including SKOV3 exposed to doxorubicin (Rogalska et al., 2011). This 
contradiction could be linked to the differences between cell lines or to the lack of data on 
other time points in this project. It is worth mentioning that hyperpolarisation is one of the 
known causes of the swelling of mitochondria that leads to their rupture and the release of 
proapoptotic proteins (Ly, Grubb and Lawen, 2003). 
The presence of AKBA significantly changed the effect of doxorubicin on Δψm leading to 
mitochondrial membrane depolarisation despite the fact that the tested dose of AKBA itself 
did not shown any effect on Δψm. This joint impact on mitochondria could be one of the 












4 Nuclear Factor kappa-light-chain-enhancer of activated B cells 
(NFκB) pathway 
4.1 Introduction 
Alongside carcinogens, inflammation is linked to carcinogenesis with estimates that 
‘inflammation contributes to the development of about 15 % of all cancer’ (Marx, 2004). The 
increase in liver cancer risk in patients with chronic hepatitis B infections is one of the 
classical examples that support this view (Marx, 2004). The review by Hanahan and 
Weinberg (2011) discusses the tumour promoting inflammation as one of the hallmarks of 
cancer. They stated a number of pieces of evidences from literature of the involvement of 
inflammation in promoting cancer such as providing tumours with growth factors to progress 
and survive and enzymes that enable tumours to metastasise. 
In an attempt to find a possible molecular link between inflammation and cancer, researchers 
investigated DNA transcription factors of NFκB protein family (NFκB1/p105, NFκB2/p100, 
RelA/p65, RelB and c-Rel), which are widely known as a hallmark of inflammation (Figure 
4.1). NFκB was found in its active form in a variety of cancers even though oncogenic 
mutations were limited to lymphoid malignancies. Apoptosis inhibition, cell proliferation 
stimulation and enhancing migratory and invasive phenotype were found to be the effects of 
the activated NFκB in tumour progression. It is not only NFκB that is involved in the link 
between inflammation and cancer, other members of NFκB pathway could play a role in 
either NF-κB-dependent or -independent manner (Karin, 2009). For example, the mTOR 
pathway can be activated by Tuberous sclerosis proteins 1 (TSC1) following phosphorylation 
by IKKβ, a regulatory kinase of NF-κB, which leads to enhanced angiogenesis and 
contributes to tumour development (Israël, 2010).  
Ovarian cancer is no exception in terms of the contribution of the activated NFκB to its 
development. For instance, the impairment in the ability of tumour-associated macrophages 
to respond to M1 activation signals in human ovarian carcinoma was associated with 
activation of the NFκB p50 homodimer (Kaltschmidt et al., 2019). P50, a cleaved product of 
P105, is inactive by itself. It needs to form a heterodimer with RelA, RelB or c-Rel or a 
P50/P50 homodimer to be active (Yu, Wan and Huang, 2009). In addition, the poor outcome 
and aggressiveness of ovarian cancer was found to be linked to the activation of NFκB 
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through IKKβ (Hernandez et al., 2010). The NFκB pathway is a logical target for treating and 
preventing cancer considering its role and relative importance in cancer cell biology. 
 
 
Figure 4.1: NFκB signalling pathway. (https://commons.wikimedia.org) 
The synergistic interaction between AKBA and doxorubicin was established in the previous 
chapters. Therefore, the aim of this chapter is to investigate the effects of AKBA, 
doxorubicin and the combination of both agents on the NFκB pathway as one of the possible 
molecular targets of the combination of AKBA and a chemotherapy drug and possibly help in 




4.2.1 Proteome Profiler Human NFκB Pathway Array 
Proteome Profiler Human NFκB Pathway Array (Catalogue Number: ARY029, R&D 
systems, USA) was used to screen the effect of AKBA (26.55 µM), doxorubicin (70 nM) and 
both agents combined together on the expression of NFκB pathway protein. The array is 
provided with only four wells and its cost is relatively high. Therefore, a few samples were 
used without a positive control. The array facilitates the simultaneous detection of 41 human 
proteins and 4 serine or tyrosine phosphorylation sites. A duplicate of capture and control 
antibodies were spotted on nitrocellulose membranes. 
The provided protocol was followed to test the effect of candidate agents on the NFκB 
pathway, see the appendix. The only difference to the original protocol is the number of cells 
seeded. The cell density per well was 3 x 105, which was based on western blot optimisations 
for A2780 (not shown). In brief, cell lysates were collected after exposing the seeded cells to 
the agents for 24 h, a timepoint which was chosen based on previous experiments to be a 
starting point. The lysates were then diluted and incubated overnight with the Human NFκB 
Pathway Array. The array was washed to remove unbound proteins and incubated with a 
cocktail of biotinylated detection antibodies. Streptavidin-HRP and chemiluminescent 
detection reagents were applied. The GeneGnome - Syngene bio imaging with GeneSys 
V1.4.1.0 software was used to take chemiluminescence images. The density of the spots were 
determined using densitometry via the ImageJ software. A reference co-ordinate provided by 
the supplier that indicates the position of the screened protein was followed to collect and 
analyse data. 
 
4.2.2 Western Blotting 
Western blotting is a technique that separates proteins based on molecular weight through the 
use of denaturing polyacrylamide gel electrophoresis (PAGE) to separate a mixture of 
proteins which are then transferred to a membrane. A protein of interest can be identified 
based on the molecular weight and use of an antibody targeting a selected protein along with 
a secondary antibody coupled to a reporter protein, such as horseradish peroxidase. 
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4.2.2.1 Equipment and materials 
All materials were obtained from Thermo Fisher Scientific (Loughborough, UK), unless 
noted otherwise. 
- Mini Gel tank and electrophoresis power supply (Invitrogen, A25977). 
- Running Buffer. 
- Bolt 4 - 12 % Bis-Tris Plus Gel. 
- iBlotTM 2 Gel Transfer Device. 
- iBlotTM 2 Nitrocellulose Regular Stacks. 
- Roller, scissors and forceps. 
- Paper towels. 
- Containers for washing and staining the blots. 
- Rocker. 
- Gel imager. 
- Acetate sheets. 
- Cling film. 
- Pipettes and tips. 
- Glass bottles. 
- Bovine Serum Albumin (BSA). 
- Primary antibody. 
- Secondary antibody. 
- 6 well plates. 
- Cell scrapers. 
 
4.2.2.2 Solutions preparation 
- 10 x Tris-buffered saline (TBS): 500 mM Tris base, 1.5 M sodium chloride. Adjust pH to 
7.5 using HCl. 
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- 20% v/v Triton X-100 in dH2O. 
- TBS-Tx100: 450 ml dH2O + 50 ml 10 x TBS + 2.5 ml 20% Triton X-100 (or 0.5 Triton X-
100). 
 
4.2.2.3 Sample preparation 
A2780 cells were seeded in 6 well plates and allowed attach and acclimatise for 24 h at 37 ºC 
in 5 % CO2. The seeding numbers were 6 x 105 cells per well for 1 h exposure and 3 x 105 
cells per well for 24 h exposure. The old medium was removed and replaced with fresh 
medium. Test agents were then added to expose the cells for the proposed period of time, 1 h 
or 24 h. The concentrations of the agents used in this experiment were based on the MTT 
data. After exposing cells for the desired time, the medium was removed and 72 µL of 
lithium dodecyl sulfate (LDS) sample buffer was added to lyse the cells and denature 
proteins. Well contents were scraped using disposable scrapers and collected in 1.5 mL 
Eppendorf tubes. Each cell lysate was sonicated using a Qsonica sonicator for 15 seconds at 
20% pulse amplification. The required volume (8 µL) of NuPAGETM Sample Reducing 
Agent was added to each sample just before adding the samples to the gels for 
electrophoresis. 
 
4.2.2.4 Gel electrophoresis 
Precast BoltTM 4-12% Bis-Tris Plus Gels (10-well) were used to run the samples prepared as 
shown in 4.2.2.3. The volume of each sample that was added to each well was 30 µL. In the 
first well, 5 µL of SeeBlueTM Plus2 pre-stained protein standard (10 proteins, 4 - 250 kDa 
molecular weight markers) was added to monitor protein migration and to serve as a protein 
ladder to identify the size of the proteins of interest. The loaded samples were run at 200 V 
using NuPAGETM MES SDS Running Buffer for 25 minutes in Invitrogen mini gel tank. The 




4.2.2.5 Protein transfer and staining 
The gels containing the separated proteins were placed on a nitrocellulose membrane in an 
assembled iBlotTM 2 Transfer Stack which were then put on the iBlotTM 2 Gel Transfer 
Device to transfer the proteins from the gel to the nitrocellulose membrane. The 
recommended program for BoltTM 4-12 % Bis-Tris Plus Gels was used (P0, 20 - 25 V, 8 - 10 
minutes ). The iBlotTM western blotting system is a dry blotting system. 
The nitrocellulose membrane was blocked using 5 % w/v BSA in TBS-Tx100 on a rocker at 
room temperature for 1 h. The primary antibody of the protein of interest was diluted in 5 % 
w/v BSA in TBS-Tx100 according to supplier instructions and added to the membranes. The 
details of the used antibodies are mentioned in Table 4.1. The membranes were placed on a 
rocker in a cold room overnight. Then, the membranes were briefly washed once and then on 
a rocker for 10 minutes using TBS-Tx100 to remove the residual primary antibodies. The 
HRP-conjugated secondary antibody was diluted and added to the membranes for 1 h at room 
temperature on the rocker, which was then followed by 10 minutes wash using TBS-Tx100. 
Table 4.1. Antibodies used for western blot. All antibodies were purchased from Abcam (Cambridge, UK). 
Antibody Dilution Description Cat No. 
Anti-cIAP1 1:250 Rabbit monoclonal ab108361 
Anti-DR5 1:500 Rabbit monoclonal ab199357 
Anti-beta Actin 1:200 Rabbit monoclonal ab115777 
Anti-Rabbit IgG 
(secondary) 




Pierce ECL Western Blotting Substrate (Thermo Scientific, UK) was used on the membranes 
as a horseradish peroxidase (HRP) substrate for enhanced chemiluminescence (ECL). 
Chemiluminsence images were immediately captured using the GeneGnome - Syngene bio 
imaging with GeneSys V1.4.1.0 software. The images were then analysed using densitometry 
via the Image Studiosoftware. Band densities were normalised against the beta-actin, internal 
or housekeeping, control. The graphs represent the percentages of the target proteins of each 
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dose to the negative control. The negative control was normalised to 100 %. Data presented 
as n=3 ± SEM. 
 
4.2.3 Statistical analysis 
The statistical significance was tested using unpaired t-tests on GraphPad Prism 8. If P<0.05, 





The possible impacts of exposing A2780 cells to AKBA, doxorubicin or both agents added 
together on NFκB pathway protein expression was studied using Proteome Profiler Human 
NFκB Pathway Array and then confirmed for selected proteins using western blot. The 
results showed that treated cells with either AKBA or doxorubicin affected the expression of 
a number of proteins. Moreover, combining AKBA with doxorubicin changed the effect of 
doxorubicin on the protein expression in some cases (Figure 4.2). The reduction of the 
expression of cellular inhibitor of apoptosis protein 1 (cIAP1) was reported as a result of 
exposing cells to AKBA or doxorubicin. This effect was increased following simultaneous 
exposure to both compounds. The other noticeable change was on the expression of the death 
receptor 5 (DR5). Where AKBA decreased the expression of DR5, doxorubicin alone 
resulted in the increase of DR5. The presence of AKBA improved the effect of doxorubicin 
on DR5 expression. Therefore, cIAP1 and DR5 were selected for further analysis using 
western blot. 
A2780 cells were exposed to AKBA, doxorubicin and both in combination for 1 and 24 h to 
confirm the changes on the expression of cIAP1 and DR5 proteins, reported before from 
proteome array data, using western blot. After 1h of exposure there was no to weak signal of 
both cIAP1 and DR5 despite the presence of sufficient amount of protein as shown by beta 
actin (β-actin), the housekeeping or loading protein (data not shown). The expression was 
apparent after 24 h for both proteins. 
The expression of cIAP1 protein was reduced as a result of exposing the cells to AKBA (26 
µM) or doxorubicin (1 µM) for 24 h, where the difference was significant (P<0.001)  
compared to the control. The effect of combining AKBA with doxorubicin was negligible 
and statistically insignificant at this time point despite the apparent difference in the graph 
(Figure 4.3). 
DR5 protein expression was decreased as a result of treating A2780 cells with 26 µM AKBA 
for 24 h (P<0.05), whereas the higher dose of AKBA (62 µM) was not as effective at this 
time point. In addition, the apparent increase in the expression of DR5 after 24 h treatment 
with doxorubicin was insignificant. The presence of AKBA with doxorubicin led to a 










Figure 4.2: The effects of AKBA and doxorubicin alone or combined with AKBA on NFκB pathway on A2780. Cells were exposed to AKBA, doxorubicin and both combined together for 24 
h then Proteome Profiler Human NFκB  Pathway Array was used to detect the impact of the tested agents on NFκB pathway. The expression of proteins is shown n=1 (A). The membrane of the 




Figure 4.3: cIAP1 and DR5 expression after exposing A2780 cells to AKBA, doxorubicin or the combination of both. Cells were treated for 24 h. 
Data is shown as n=3 independent experiments ± SEM. AKBA 62 µM is shown as n=2 therefore error bar is missing. *P<0.05 and **P<0.01 
compared to the control. 
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4.4 Discussion 
The role of NFκB pathway in both inflammation and cancer provides the rationale behind 
targeting the pathway in cancer therapy. The constitutive activation of NFκB is found in a 
number of cancers including ovarian cancer, which contributes to the survival, escaping 
apoptosis and relatively rapid cellular growth in cancers. The NFκB pathway composite 
proteins are also involved in a number of cellular processes and not limited to the pathway 
itself. In this chapter, the impact of AKBA, doxorubicin and both combined on the NFκB 
pathway was investigated and will be discussed. 
The common trend that was reported in this project is the reduction of the expression of a 
number of proteins in the NFκB pathway as a result of the exposure to selected doses of 
AKBA, doxorubicin or a combination of both agents. Transcription factors of NFκB remain 
inactive in the cytoplasm due to its binding to IκB-α (NF-kappa-B inhibitor alpha), a family 
member of inhibitors of NFκB (IκB) (Potz et al., 2017). The expression of IκB-α protein was 
slightly increased in the cells exposed to AKBA alone. In contrast, doxorubicin exposure led 
to the reduction of the expression of IκB-α, which was interestingly normalised again after 
combining AKBA with doxorubicin. The other tested member of IκB family is IκB-ε, which 
is complexed predominantly to RelA and c-Rel along with IκB- β (Whiteside et al., 1997). 
The expression of IkB-ε in the treated cells was low compared to the untreated control. These 
proteins may be contributing to inhibition of NFκB signalling. 
The observed changes in the expression of examined members of IκB family brings the 
inhibitor of nuclear factor kappa-B kinase (IKK) family under the scope. IKK is a 
multicomponent protein complex (IKK-α, IKK-β and IKK-γ/NEMO) that is responsible for 
the inactivation of IκB in response to stimuli. IKK inactivates IκB via phosphorylation 
causing protein degradation which leads to the release of NFκB (Potz et al., 2017). The 
expression of IKK-α and IKK-γ was reduced in the cells exposed to AKBA alone, whereas 
IKK-β expression was slightly increased. This confirms results by Syrovets et al. (2005) 
where the inhibition of NFκB by AKBA was linked to its direct inhibitory effect on IKK. The 
other related observations in the current project are the reduced expressions of IKK-α, IKK-β 
and IKK-γ in the cells exposed to doxorubicin alone and further reduction of IKK-α and 
IKK-β in the presence of AKBA was reported. 
B-cell lymphoma/leukemia 10 (BCL10) is one of the known regulators of apoptosis and 
activators of NFκB (Wang et al., 2001; Zhou et al., 2004). The expression of BCL10 was 
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reduced in the cells treated with AKBA, doxorubicin and both agents combined. BCL10 
reduction (Karin, 2006) combined with overall inactivation of NFκB pathway may enhance 
the probability of apoptosis contributing to the reported synergism between AKBA and 
doxorubicin. 
Fas (CD95), a prototypic death receptor, induces apoptosis and activates NFκB through fas-
associated protein with death domain (FADD), which induce NFκB activity via caspase 8 and 
RIP (receptor-interacting protein kinases) (Kreuz et al., 2004). The expression of both Fas 
and FADD was not affected by exposing cells to AKBA. This agrees with the findings that 
were reported by Liu et al. (2002) where AKBA induced apoptosis in colon cancer HT-29 
cells through caspase 8 in a pathway that was independent on Fas/FasL interaction. They 
state that expression of Fas was not changed when cells treated with AKBA. While Fas 
expression was slightly reduced after exposing the cells to doxorubicin, FADD expression 
was almost halved compared to the untreated control. Similar observations on breast cancer 
cells MCF-7 were reported (Liu and Chang, 2011). 
Members of inhibitor of apoptosis (IAP) protein family have been targeted to treat cancer by 
developing agents that inhibit their function to serve as a promising approach to induce 
apoptosis in cancer cells (Straub, 2010). Changes in IAPs contribute to chemoresistance, 
disease progression and poor prognosis of a number of cancers. In addition to their primary 
function in regulating caspases, IAPs are involved in other cellular processes including the 
activation of NFκB transcription factors (Gyrd-Hansen and Meier, 2010). Based on the 
proteome analysis results that was then confirmed by western blot, cIAP1 protein expression 
was down-regulated by AKBA (26 µM) and doxorubicin (1 µM). Similar but less noticeable 
impacts were reported on cIAP2. Roy et al. (2016) state that IAP1 is one of the molecular 
targets of boswellic acids. Combining AKBA with doxorubicin has not affected the inhibitory 
effect of doxorubicin on cIAP1. Even though there was no significant change in the effect of 
doxorubicin on cIAP1 when combined with AKBA compared to doxorubicin alone, more 
time points and a wider range of doses may lead to a more conclusive data.  
Interleukin 17 receptor A (IL-17 RA) is a membrane protein that binds to interleukin 17A 
(IL-17A). NFκB is one of the downstream targets of IL-17A in many cells (Gu, Wu and Li, 
2013). IL-17A increased the expression of MMP2 and MMP9 via NFκB activation, which 
was linked to promoting metastasis in hepatocellular carcinoma (Li et al., 2011). While the 
expression of IL17 RA was slightly reduced by AKBA, it was halved by doxorubicin. In the 
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presence of AKBA, the reduction in expression of IL-17RA induced by doxorubicin was 
largely counteracted. 
One of the upstream activators of NFκB is interleukin-1 receptor-associated kinase 1 
(IRAK1), the first discovered member of interleukin-1 receptor-associated kinases (IRAKs). 
IRAKs are important in a number of normal and pathological cellular processes including 
cellular differentiation, apoptosis and inflammation. To activate NFκB, Phosphorylated 
IRAK1 binds to E3 ubiquitin ligase (TRAF6) (Rhyasen and Starczynowski, 2015). IRAK1 
could be a target to prevent metastasis, resistance and reduce the size of solid tumours, where 
it was found overexpressed in various types of cancers and contributes to tumorigenesis 
(Zhang et al., 2014; Wee et al., 2015; Yang et al., 2019). In this study, the expression of 
IRAK1 was reduced in the cells treated with AKBA and doxorubicin alone. Further reduction 
in the expression of IRAK1 was observed when the two agents were combined suggesting 
reduced NFκB phosphorylation and therefore reduced NFκB signalling. 
The following NFκB transcription factors: NFκB1, NFκB2, RelA (and Rela pS529) and c-
RelA expressions were examined in this NFκB proteome analysis after exposing cells to the 
tested agents for 24 h. Their expression was reduced when cells were treated with AKBA, 
doxorubicin or both combined compared to the untreated control. The presence of AKBA 
with doxorubicin slightly reduced the effect of doxorubicin on the transcription factors even 
though it remained lower than the control. Changes in the expression of NFκB1 and RelA 
were more pronounced than the other factors. This is in line with the other observations 
discussed above where a general inhibition of NFκB was shown. 
The participation of p53 in a broad range of important cellular events, such as cell cycle 
regulation, DNA repair and apoptosis induction, and for the fact that p53 abnormality is 
widely found in various types of cancers makes it one of the important proteins to explore 
and understand (Zhou, Hao and Lu, 2019). Mutant p53 contribution to tumour survival and 
invasion through TNFα-dependent activation of NFκB is one of the examples that explains 
the involvement of p53 in NFκB pathway (Mantovani, Walerych and Sal, 2017). In this 
project, it was reported that AKBA reduced the expression of p53 while doxorubicin 
increased its expression and the expression of the phosphorylated p53 (pS46). Interestingly, 
the impact of doxorubicin on p53 expression was reduced by AKBA. This could be used as 
an indicator that AKBA induced cell cycle arrest and apoptosis in a p53-independent manner 
(see section: 1.2.2). 
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TRAF2 (tumour necrosis factor receptor (TNFR)–associated factor (TRAF)) belongs to the 
TNF receptor-associated factor (TRAF) family and it is one of the activators of NFκB (Zhang 
et al., 2011). The expression of TRAF2 was decreased in the cells treated with AKBA or 
doxorubicin. Moreover, combining AKBA with doxorubicin led to further reduction in the 
expression of TRAF2. These observations confirm the other discussed data where a down-
regulation of a number of NFκB activators was reported. 
Death receptor 5 (DR5, TRAIL R2 (tumour necrosis factor-related apoptosis-inducing ligand 
receptor 1)) expression is regulated by NFκB among other regulators. Activated NFκB up-
regulates the expression of the DR5 by cooperating with p53, where both proteins induce 
apoptosis (Shetty et al., 2005). DR5 expression was first tested using the NFκB proteome 
analysis then was selected to be the second candidate to confirm using western blot. AKBA 
reduced the expression of DR5 when used at 26 µM for 24 h, which was relatively non-toxic. 
On the other hand, the expression of DR5 was not significantly changed in the cells exposed 
to doxorubicin neither in the cells exposed to doxorubicin combined with AKBA (26 µM). 
Similar to cIAP1, the effect of different agents on the expression of DR5 needs more 
exploration.  
To sum up, AKBA and doxorubicin alone or combined at the tested doses and time points 
showed the ability to downregulate NFκB using the NFκB proteome analysis. Considering 
the synergistic interaction between the agents shown in previous chapters, NFκB could be 
one of the shared targets through acting on different proteins in the pathway. This impact on 
the NFκB pathway needs more investigation using other time points and wider range of the 
concentrations, which could provide more information on the involvement of NFκB on the 
interaction between AKBA and doxorubicin. For example, DR5 and cIAP1 protein 
expression were triggered sometime after 1 h and before 24 h from the exposure, which can 
be seen from the absence of the signal at 1 h. The other suggested approach to tackle 
limitations in this project is to repeat the NFκB proteome analysis at least twice to apply a 
more robust statistical analysis on the data. Moreover, NFκB activity, rather than expression, 
could be monitored overtime using a technique described by Badr et al. (2009) to understand 
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5 Nuclear Factor E2-related Factor 2 (Nrf2) and Reactive Oxygen 
species (ROS) 
5.1 Introduction 
5.1.1 Nuclear Factor E2-related Factor 2 (Nrf2) and Reactive Oxygen species (ROS) 
Exogenous, e.g. UV or drugs, and endogenous, e.g. ROS, stresses could threaten the normal 
functionality of cells, leading to DNA damage, cell destruction or could induce 
tumorigenesis. A number of molecular components could be involved in the cellular defence 
mechanisms. The key defensive pathway against oxidative and electrophilic stress is Keap1-
Nrf2 signalling pathway. Nrf2 is normally guarded by actin-associated Keap1 protein in the 
cytoplasm. Keap1 releases Nrf2 in response to the stress signalling, which in turn move to the 
nucleus and binds to a cis-acting enhancer called antioxidant-response element (ARE). This 
binding regulates the ARE-mediated antioxidant enzyme gene expression of a variety of 
enzymes involved in cellular detoxification processes, e.g GSTA2 (glutathione S-transferase 
A2), NQO1 (NADPH: quinone oxidoreductase 1) and HO-1 (Heme Oxygenase 1) (Lee and 
Johnson, 2004; Kaspar, Niture and Jaiswal, 2009; Nguyen, Nioi and Pickett, 2009). The main 
function of this mechanism is maintaining the redox balance in cells, which helps in the cell 
survival. 
Nrf2 cytoprotective ability is linked to cancer chemoprevention in normal and premalignant 
cells. A variety of phytochemicals, extracted from different plants, with potent chemo-
preventive activities were found to be Nrf2 inducers. However, Nrf2 could also be part of 
tumorigenesis and cancer progression. It could be involved in chemoresistance by protecting 
cancer cells from the chemical stress caused by chemotherapeutic agents (Lau et al., 2008; 
Kansanen et al., 2013). One of the ways that Nrf2 contributes to chemoresistance is the 
regulation of efflux transporters such as p-glycoprotein (P-gp) (Jeddi et al., 2017; Sadeghi et 
al., 2018). This dual role seems to be controlled by the microenvironment of the cell. A 
number of target proteins are regulated by Keap1-Nrf2 signalling pathway (Table 5.1). 
In this chapter, the effects of the tested agents on Nrf2 expression are examined in an attempt 
to explore if it is one of the possible reasons of the apparent antagonism between AKBA and 
cisplatin. The other part of this chapter focuses on the possible impacts of the agents on ROS 




Table 5.1: Key target proteins in Keap1-Nrf2 signalling pathway categorisation (Jeddi et al., 2017).  
Antioxidants Detoxification enzymes Membrane transporters 
Heme oxygenase-1 (HO-1) 







Sulfiredoxin 1 (Srx1) 







oxidoreductase 1 (NQO1) 
Ferritin heavy (FTH1) 
Ferritin light (FTL) chains 












Breast cancer resistance 
protein BCRP/ABCG2 
 
5.1.2 Permeability glycoprotein (P-gp) expression 
As discussed in the introduction of this thesis, drug efflux from cancer cells is one of the 
mechanisms behind multidrug resistance (MDR). One of the molecular events that could lead 
to the efflux is the overexpression of MDR-1 gene, also called ABCB1 gene, which encodes 
an ATP cassette transporter protein called permeability glycoprotein (P-gp). In addition to the 
primary physiological role of P-gp by helping cells to remove toxins and xenobiotics through 
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the plasma membrane, it is overexpressed in many cancer types, including ovarian cancer, 
and involved in other diseases such as Alzheimer’s disease. The structure of P-gp allows it to 
react with a broad range of sizes of cationic amphipathic molecules. P-gp is 170 kDa 
composed of two pseudo-symmetrical halves (Gottesman and Pastan, 2015; Katayama et al., 
2015; McCormick, Vogel and Wise, 2015). 
P-pg overexpression in chemoresistant cancer cells causes drug efflux leading to the 
reduction of the intracellular concentration of therapeutic agents and their cytotoxicity. 
Doxorubicin is one of a wide spectrum of antitumor agents that could be affected by the 
expression of P-gp in tumour cells. Considering its importance in MDR, targeting P-gp and 
its substrates using synthetic agents or natural product extracts is one of the emerging 
approaches to overcome drug resistance in cancer treatment (Raghava and Lakshmi, 2012; 
Abdallah et al., 2015). 
The synergistic interaction between AKBA and doxorubicin was reported earlier in this 
project (see chapter 2). Establishing the effects of each of the agents alone or both combined 
on P-gp could help in revealing one of the molecular targets of the agents or could provide an 
explanation of the interaction between them.  
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5.2 Methods 
5.2.1 Western blotting for Nrf2 
The western blot procedure mentioned in 5.2.2 was followed. The antibodies used here are 
listed in Table 5.2. 
Table 5.2. The antibodies. All antibodies were purchased from Abcam. 
Antibody Dilution Description Cat No. 
Anti-Nrf2 1:1000 Mouse monoclonal ab89443 
Anti-HO-1 1:500 Mouse monoclonal ab13248 
Anti-beta Actin 1:250 Mouse monoclonal ab8226 
Anti-Rabbit IgG 1:2000 Rabbit HRP conjugated ab6728 
 
5.2.2 Reactive oxygen species (ROS) assay 
A quantitative microplate assay for ROS detection was used to assess the effect of AKBA, 
doxorubicin, cisplatin and AKBA combined with either doxorubicin or cisplatin on ROS 
generation on A2780. In this assay, ROS activity in cells is measurable by using a 
fluorogenic dye, 2’,7’ –dichlorofluorescin diacetate (DCFDA). Cellular esterases deacetylate 
DCFDA to a non-fluorescent compound, which is retained in the cell. The compound can 
then be oxidised by various oxidising species ROS to produce 2’, 7’ –dichlorofluorescein 
(DCF), which is highly fluorescent. 
Cells were seeded at 4 x 105 cells per well in black 96-well plates with clear bottom in a 
phenol red free RPMI-1640 +10 % NCS. Cells were incubated at 37 °C in 5 % CO2 for 24 h 
to attach and acclimatise. The medium was removed and the cells were washed once with 
PBS. The cells were then incubated with with 20 μM DCFDA (Catalogue Number: D399, 
Fisher, UK) in PBS for 45 minutes at 37 °C in 5 % CO2. The cells were then washed once 
with PBS to remove non-absorbed DCFDA. Fresh PBS was added with various 
concentrations of the agents and cells exposed the cells for 1 h, at 37 °C in 5 % CO2. 
Fluorescence signal was monitored at excitation/emission (475/500-550) using a microtiter 
plate reader (GloMax® Discover System, GM3000, Promega Corporation, USA).  
For 24 h exposure, phenol red free medium + 10 % NCS was used with the agents instead of 
PBS after allowing cells to acclimatise and staining them with DCFDA. Cells were then 
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incubated at 37 °C in 5 % CO2 for 24 h with selected doses of the tested agents. The medium 
was then removed and cells were washed once with PBS. Finally, fresh PBS was added and 
the plates were taken to quantify the fluorescence at excitation/emission (475/500-550) using 
the microtiter plate reader (GloMax® Discover System, GM3000, Promega Corporation, 
USA). The background, that may result from fluorescent compounds in the cells or culture 
medium, was subtracted using unstained cells as baseline of the experiment. The percentages 
of each dose of the negative (untreated) control was calculated using Excel. 
 
5.2.3 Western blotting for Pgp 
The western blot procedure mentioned in 5.2.2 was followed. The antibodies used here are 
listed in Table 5.3. The reagents used in this chapter are AKBA (26 and 62 µM) and 
doxorubicin (70 nM and 2 µM). A2780 cells were exposed to the agents separately or 
combined for 1 and 24 h.  
Table 5.3: The antibodies. All antibodies were purchased from Abcam 
Antibody Dilution Description Cat No. 
Anti-Pgp 1:500 Rabbit monoclonal ab170904 
Anti-beta Actin 1:200 Rabbit monoclonal ab115777 
Anti-Rabbit IgG 1:2000 Rabbit HRP conjugated ab6728 
 
5.2.4 Flow cytometry 
After treating A2780 cells with according to the planned approach, samples were run in BD 
Accuri C6 plus flow cytometer. The protocol provided by Abcam was followed (See: 
https://www.abcam.com/protocols/direct-flow-cytometry-protocol). Mouse monoclonal 
[UIC2] to P Glycoprotein (Phycoerythrin) (ab93590, Abcam) was used to determine the 
expression of P-gp. Mouse monoclonal IgG2a (ab91363) was used as an isotype control. 
Collected data were analysed using FlowJo (V10, USA). One experiment was performed 
because of the limited access to the flow cytometer. 
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5.2.5 Statistical analysis 
The statistical significance was tested using unpaired t-tests on GraphPad Prism 8. If P<0.05, 




5.3.1 Nrf2 expression modulation 
The effect of AKBA, cisplatin, doxorubicin or either combined with AKBA on Nrf2 protein 
expression on A2780 cell was examined at two different time points 1 and 24 h of exposure 
using western blot (Figure 5.1). Heme Oxygenase 1 (HO-1) protein expression was used as 
an indicator of Nrf2 activity, where Nrf2 activation activates the expression of HO-1 among 
other cellular defence genes. 
The expression of Nrf2 was not affected after exposing cells to AKBA for 1 h neither for 
24h. HO-1 expression was slightly elevated at 26.55 µM and downregulated at 62 µM AKBA 
in the cells exposed for 1 h. 
The second approach considered exposing cells to cisplatin or cisplatin combined with 26 
µM AKBA. There was a reduction in the expression of both proteins after 1 h of the exposure 
to cisplatin. The reduction was significantly different to the control. The presence of AKBA 
did not change the effects of cisplatin on Nrf2 and HO-1. The results of 24 h exposure 
showed negligible/no difference in the expression of Nrf2 and HO-1 in the cells exposed to 
cisplatin compared to the contol or cisplatin combined with AKBA compared to the control 
and cisplatin alone. 
The final approach was by treating cells with doxorubicin alone or combined with AKBA for 
1 or 24 h. Similar to cisplatin, a reduction in the expression of both Nrf2 and HO-1 proteins 
was reported after 1 h of the treatment. The presence of AKBA did not affect the effect of 
doxorubicin on both proteins. Following 24 h exposure, Nrf2 level of expression was similar 
to the control at 62 nM, whereas a significant increase was noted at 2 µM. A statistically 
significant increase in Nrf2 production was reported as a result of the presence of AKBA 
with doxorubicin compared to doxorubicin solely at both doses. On the other hand, 
significant downregulation of HO-1 was observed following the combination of AKBA with 






Figure 5.1: Nrf2 and HO-1 expression following the exposure of A2780 to AKBA, cisplatin, doxorubicin or either combined with AKBA for 1 
and 24 h. Cis = cisplatin and Dox = doxorubicin. The expression of the proteins was determined using western blot. Data represents at least 3 
independent experiments ± SEM. *P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001 compared to the control. **P<0.01compared to the same 
dose in the absence of AKBA. 
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5.3.2 Reactive oxygen species (ROS) generation 
The impact of various treatment approaches used in this project on ROS generation in A2780 
cells was investigated using DCFDA, a fluorogenic dye (Figure 5.2). Cells were treated with 
the tested agents for 1 or 24 h. Exposing the cells to AKBA for 1h resulted in a significant 
reduction in ROS levels, whereas ROS generation was similar to the untreated cells after 24 
h. Similar observations where reported following the exposure to different concentration of 
cisplatin for 1 and 24 h. The effect of cisplatin on ROS formation was not significantly 
changed as a result of the presence of AKBA at both time points. Finally, the levels of ROS 
were not affected after treating the cells with doxorubicin for 1 h. In contrast, ROS levels 
were reduced in a dose dependent manner after 24 h of treating cells with doxorubicin. There 
was no reported changes to the effects of doxorubicin on ROS after combining it with AKBA 





Figure 5.2: ROS generation in A2780 cells following the exposure to AKBA, cisplatin, doxorubicin or either of the 
chemotherapies combined with AKBA. The levels of the ROS were determined using DCFDA as described in the methods 
section. Data represents mean n= 3 independent experiments ± SEM. *P<0.05 and **P<0.01. 
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5.3.3 P-gp expression modification by AKBA and doxorubicin 
The impact of AKBA, doxorubicin and both agents combined on P-gp expression in A2780 
was studied using western blot. The cells were treated with selected doses of the agents for 1 
and 24 h. Collected cell lysates were run and band intensities were calculated. The expression 
of P-gp was not altered after 1 h of exposing cells for both doses of AKBA (26 and 62 µM). 
A significant increase in the expression of P-gp was reported at 62 µM AKBA after 24 h of 
the exposure (Figure 5.3). 
The expression of P-gp in the cells exposed to doxorubicin at 2 µM for 1h was significantly 
decreased compared to the untreated cells, while the change of P-gp expression in cells 
exposed to 70 nM doxorubicin was negligible at both time points. It seemed that P-gp 
expression is higher than the control in the cells exposed to 2 µM doxorubicin for 24 h 
(P=0.07). More repeats of the experiment may reveal a significant effect. The presence of 26 
µM AKBA with both doses of doxorubicin has shown no impact on the effects of 
doxorubicin on P-gp expression at both time points 1 and 24 h (Figure 5.3). 
 
5.3.4 Testing the effects of selected agents on P-gp expression using flow cytometry 
The flow cytometry analysis of the expression of P-gp will be discussed here. There was an 
increase in P-gp expression after exposing A2780 cells to AKBA. However, there was a 
slight reduction in the expression of P-gp as a result of treating the cells with doxorubicin. 
Further reduction in the expression was reported when AKBA was combined with 
doxorubicin at both doses 70 nM and 2 µM. More experiments are required to confirm these 









Figure 5.3. The expression of P-gp in A2780 exposed to AKBA, doxorubicin and a combination of both agents for 1 and 24h. Cells were 
treated with the selected doses for 1 and 24 h. The percentages of the expression of P-gp in A2780 compared to control cells are shown as three 
independent experiments ± SEM (A). B shows the bands on the membrane after running samples using western blot. The graph (C) shows the 
percentages of fluorescence of various doses compared to untreated cells (n=1) following the exposure of cells to the agents for 24 h.  
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5.4 Discussion 
5.4.1 Nuclear Factor E2-related Factor 2 (Nrf2) and Reactive Oxygen species (ROS) 
Generation 
In normal cells the transcription factor Nrf2  plays a key role in in the cellular defence 
mechanism against ROS and other potentially toxic agents to maintain the redox haemostasis, 
which is necessary for cells health. Nrf2, however, can be used by cancer cells to survive 
various endogenous and exogenous stresses through inducing the expression of about 500 
genes that encode proteins with antioxidant and cytoprotective functions. HO-1 is a particular 
protein that helps cancer cells to grow and resist chemotherapies due to its antioxidant and 
antiapoptotic effects. It was reported that Nrf2 and HO-1 are overexpressed in various cancer 
types including ovarian carcinoma (Furfaro et al., 2016). The influence of AKBA, cisplatin, 
doxorubicin or either of the conventional chemotherapies combined with AKBA on Nrf2, 
HO-1 and ROS generation was examined in this chapter. The main purpose of this 
exploration was studying the possible molecular pathways involved in the antagonistic 
interactions between cisplatin and AKBA. 
Induction of Nrf2/HO-1 defence mechanism by AKBA is one of the suggested reasons 
behind the antagonistic interaction between cisplatin and AKBA. It was reported that Nrf2 is 
one of the factors that induce cisplatin resistance in ovarian cancer cell (Bao et al., 2014; Wu 
et al., 2017)..  However, Nrf2 expression was only reduced by cisplatin after 1 h, whereas its 
expression was similar to the untreated cells in the cells exposed to cisplatin for 24 h and/or 
AKBA for 1 h and 24 h. Although the results in this project do not support the involvement 
of Nrf2/HO-1 pathway in the reported antagonistic interaction between AKBA and cisplatin, 
more time points and a wider range may reveal a more conclusive outcomes. The other way 
that may help in building a better understanding is measuring the effect of the tested agents 
on the activity of Nrf2 rather than the protein expression. 
In addition, it was stated that AKBA cytoprotective effect against doxorubicin induced 
hepatotoxicity may occur due to the antioxidant activity of AKBA that might happen through 
modulation of the Nrf2/HO-1 pathway (Barakat et al., 2018). This published evidence could 
raise questions about the reported synergistic interaction between AKBA and doxorubicin 
despite the increased expression of Nrf2 in the cells exposed to doxorubicin in the presence 
of AKBA compared to the control and cells exposed to doxorubicin alone for 24 h. The 
proposed answer to this argument is the reduced expression of HO-1 in the cells treated with 
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both agents together, which could be used as a way to measure Nrf2 activity. The other 
speculated explanation is the molecular differences between normal and cancer cells. 
Therefore, it is reasonable to assume that AKBA, doxorubicin or Nrf2 function differently in 
different environments. It is also logical to say that there are other molecular targets that lead 
to the synergistic interaction between AKBA and doxorubicin such as NFκB, which in turn 
could contribute to overcoming triggered Nrf2/HO-1 defence mechanisms. 
With regards to ROS, cells were able to retrieve the balance of generated ROS after 24 h of 
exposing them to AKBA or cisplatin, while a reduction of ROS was reported at 1 h in the 
cells treated with AKBA or cisplatin. The reduced ROS formation by cisplatin at 1 h 
coincided with down-regulation of Nrf2 and HO-1. This may indicate that the antioxidant 
activity, at this particular time point and the used doses, is a result of a mechanism other than 
Nrf2/HO-1. Uttara et al. (2009) classified antioxidants based on their mechanism of action 
into four classes: direct (non-enzymatic), indirect, metabolic and metal containing. 
Doxorubicin, on the other hand, reduced ROS levels in the cells treated for 24 h in a dose 
dependent manner. 
The antagonistic interaction between AKBA and cisplatin could not be linked to Nrf2/HO-1 
pathway in this project. Further experiments are required to explore the possibility of the 
involvement of the pathway in the antagonistic interaction between AKBA and cisplatin. This 
could benefit from applying different experiments such as testing the activity of Nrf2 in the 
treated cells using a more extensive measure of Nrf2 transcriptional activity (Czauderna et 
al., 2018). In addition, examining various treatment approaches are recommended to avoid 
the antagonistic interaction. Pre-exposing cells to AKBA for 1 or 2 h before treating cells 
with cisplatin is one of the suggested approaches considering the increased expression of 
Nrf2 occurs at some point between 1 and 24 h. According to Sirota, et al. (2017), caffeic acid 
interaction with cisplatin on ovarian cancer models was dependent on the treatment approach. 
While pre-exposing cells to caffeic acid for 6 h caused the cell to be resistant to cisplatin, 
exposing them to caffeic acid and cisplatin simultaneously sensitised the cells to cisplatin. 
 
5.4.2 P-gp expression modification by AKBA and doxorubicin 
In an attempt to investigate the molecular events that could contribute to the observed 
synergistic interaction between AKBA and doxorubicin, P-gp protein expression was 
evaluated in the cells treated with AKBA, doxorubicin or both agents combined. 
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Overexpressed P-gp is one of the main reasons that give rise to chemoresistance in various 
types of cancers. In a study by Singh and Lamprecht (2015), nanoparticles loaded with P-gp 
inhibitors sensitised the resistant cell line A2780ADR to doxorubicin. Consequently, 
targeting P-gp is one of the promising approaches to overcome drug resistance (Bao et al., 
2011; Yamagishi et al., 2013; Syed et al., 2017; Nanayakkara et al., 2018). 
The results in this thesis do not support the hypothesis that P-gp is one of the molecular 
targets when trying to explain the synergistic interaction between AKBA and doxorubicin. 
The expression of P-gp in the cells treated with doxorubicin alone was lower than the 
negative control after 1 h and similar to the control after 24 h. This was not changed by 
combining AKBA (26 µM) with doxorubicin. It could be that the doses and the chosen time 
points are not enough or the approach of testing needs to be changed. 
On the other hand, the high dose of AKBA (62 µM) alone induced the expression of P-gp. 
This could mean that the impact of AKBA on P-gp is dependent on the dose or the cellular 
condition, i.e. AKBA modulated the expression of P-gp in favour of the chemotherapy 
efficacy. 
Further confirmative tests are required to support or refute current observations or the 
hypothesis. One of the tests could be examining the activity of P-gp in response to the tested 
agents. The other approach could involve comparing the expression and/or activity of P-gp in 
A2780 to its doxorubicin counterpart A2780ADR. Moreover, the reported impact of AKBA 
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6 General Discussion, Conclusions and Future Work 
Ovarian cancer is a difficult disease to treat and is usually diagnosed in a late stage. It can 
metastasise to the surrounding environment in a unique way in the early stages (Lengyel, 
2010). Following surgery and chemotherapy, ovarian cancer is able to relapse and develop 
resistance to first line chemotherapy, which could result from intrinsic or acquired resistance 
(Pokhriyal et al., 2019). Development of new treatment regimens to treat ovarian tumour is 
crucial. A large number of the available drugs used to treat cancer were discovered primarily 
in plants and thus phytotherapeutic compounds may provide a valuable addition to the 
treatment of this disease. Potential anti-tumour activity of BSE and BAs against various types 
of tumours is one of the encouraging reasons to explore them in this project. 
 
6.1 AKBA and BSE cytotoxicity towards ovarian cancer cells and possible molecular 
targets 
AKBA cytotoxicity towards ovarian cancer was addressed, for the first time, by AlSalmani et 
al. (2013) as part of a PhD project under the supervision of Dr. Evans, at the University of 
Leicester. In this thesis we confirm the potential anti-cancer activity against ovarian cancer 
models using A2780, A2780cis, A2780ADR and OVCAR4 cell lines and investigated its 
interaction with selected conventional chemotherapies, cisplatin, paclitaxel and doxorubicin, 
which will be discussed with more details in the next few paragraphs. Furthermore, the 
cytotoxicity of frankincense extracts were tested on A2780 and A2780cis. The ethanol 
extracts showed potential anti-cancer activity as evidenced by the its toxicity towards the 
examined ovarian cancer lines (A2780 and A2780cis), which agrees with published literature 
on the anti-cancer activity of BSEs on other types of cancer. The proliferation of 
hepatocellular carcinoma cells, HepG2 and Hep3B, was inhibited by BSE with the following 
EC50s: 21.21 ± 0.92 and 18.65 ± 0.71 µg/mL, respectively (Khan et al., 2014), which are 
similar to the reported EC50s in our project for A2780 (14 ± 2 µg/mL) and for A2780cis (11.5 
± 3 µg/mL) despite the differences in the cell lines, extraction solvents (methanol vs ethanol) 
and exposure time (72 h vs 24 h). They also stated that AKBA was 5 % w/w and KBA about 
2 % w/w of the prepared extract, which suggests the involvement of other bioactive 
molecules in the cytotoxicity of the extract. They also observed an increase in caspase 3 
activity and in the levels of tumour necrosis factor alpha (TNFα) and Interleukin 6 (IL-6) 
combined with a decrease in NFκB protein expression in the cells treated with BSE 
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indicating to the strong involvement of apoptosis induction in the reported anti-cancer 
activity of the extract. In addition, it was reported that BSE was effective against the induced 
colon cancer in a mouse model, where tumour formation was significantly reduced in animals 
supplemented with BSE in their daily diet compared to the control group (Chou et al., 2017). 
Based on the present results and the discussed findings by the other researchers, it could be 
useful to assess BSEs interaction with chemotherapies or the interaction between single 
components of the extracts in vitro and in vivo using these ovarian cancer models. 
The efficacy of AKBA on the tested cell lines (A2780, A2780cis, A2780ADR and OVCAR4) 
was similar in spite of the supposed molecular variability between them. It was as toxic 
towards the resistant cell lines A2780cis and A2780ADR as it was to their sensitive parent 
A2780 after 24 h with EC50s: 35.64 ± 0.78, 30 ± 2 and 30.76 ± 1.71 µM, respectively. 
Moreover, it was also toxic to the HGSOC model, OVCAR4, with a slightly higher EC50 
(40.3 ± 4 µM). The reported toxicity of AKBA on A2780 (EC50 ~22 µM) and A2780cis 
(EC50 ~ 18.5 µM) by Al-Salmani was slightly higher, which could be caused by the 
difference in the way the data was generated. The range of the doses used by Al-Salmani was 
between 5 and 50 µM (a total of 5 doses), whereas the range in the present project was 
between ~ 4 and 72 µM (a total of 8 doses). Comparable results were reported on other cell 
lines by other researchers. AKBA was effective against a Taxol resistant human ovarian 
cancer cell line A2780/Taxol with the EC50 ~ 51 µM (Jin et al., 2019). In a study by Li et al. 
(2018), the growth of U251 and U87-MG, human glioblastoma cell lines, was inhibited by 
exposing cells to AKBA for 24, 48 and 72 h, where the EC50 values were reduced overtime. 
They were, respectively, ~ 28, 22 and 19 µM for U251 cells and ~ 32, 24 and 19 µM for 
U87-MG cells (Al-Salmani, 2017). This was not the case in the current project when cells 
exposed to AKBA for 48 h, where no changes to the EC50 was observed (data not shown). 
Considering the effectiveness of AKBA in reducing cancer cells viability based on current 
findings and the given examples of published articles, the impact of AKBA on the cell cycle, 
Δψm, NFκB pathway, Nrf2/HO-1 pathway, ROS generation and P-gp expression was 
investigated attempting to understand the possible molecular mechanisms and targets that 
contribute to its cytotoxicity and its interaction with the selected chemotherapies. 
It is clear that AKBA interferes with ovarian cancer cell proliferation by inducing cell cycle 
arrest at G0/G1 phase in A2780 cells that were exposed to AKBA for 24h. This was observed 
at the highest tested dose (62 µM) but not the other two doses (15 and 31 µM), which may 
mean that the other two doses require more time to exert their effect on the cell cycle in a 
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detectable level. Similarly, AKBA-induced cell cycle arrest at G1 was reported in colon 
cancer cells (Liu, Huang and Hooi, 2006) and prostate cancer cells (Yuan et al., 2008), which 
was associated with increased expression of p21 and decreased expression of G1 phase 
cyclins (cyclin D1 and cyclin E) and CDKs 2 and 4. They state that the up-regulated 
expression of p21 was independent on the p21 gene potent transactivator, p53, considering 
the reported observation that AKBA downregulated p53 expression. Consistent with their 
findings, cell cycle was arrested at G1 and the expression of p53 was reduced by AKBA in 
the present project (see chapters 3 and 4). Further investigations are required to determine the 
mechanisms in which AKBA initiates cell cycle arrest at G1 by examining the molecular 
changes on both genetic and protein levels. Exploring this effect at various time points with a 
wider range of doses could lead to a better understanding of the impact of AKBA on the 
cycle. The effect of AKBA on the cell cycle coincided with the accumulation of DNA 
fragments at sub-G1, which will be discussed with cell death in the next paragraph. 
As discussed earlier, the accumulation of fragmented DNA at sub-G1 in the cell cycle 
analysis is a widely used as marker of apoptosis since the internucleosomal DNA 
fragmentation is one of the hallmarks of apoptosis. However, it is stressed that DNA 
accumulation at sub-G1 must not be used solely as an apoptosis marker, should be interpreted 
with caution and other confirmative, more specific, tests should be considered (Kajstura et 
al., 2007). The percentage of the events at sub-G1 was ~ 8 fold higher in the cells exposed to 
62 µM AKBA for 24 h than in the untreated cells. This was not reported in the other tested 
two doses (15 and 31 µM) at this time point, which could be explained by either that the 
lower doses require more time or by the lack of reliability of using DNA hypodiploid (sub-
G1) as an indicator of apoptosis. The former explanation is more apparent considering that 
changes in the Δψm could only be seen at around 50 µM and above. In a study by Hoernlein 
et al. (1999), sub-G1 peaks were observed after 4 h of exposing HL-60 cell to 50 µM AKBA, 
which was interpreted by the ability of AKBA to induce spontaneous apoptosis. In contrast, it 
was suggested that AKBA did not trigger apoptosis in a prostate cancer cell line, LNCaP, 
based on the unchanged percentage of sub-G1 compared to the untreated control even though 
cells were exposed to 30 µM (EC50 ~ 20 µM) AKBA for 48 h (Yuan et al., 2008). The other 
possibility is that dead cells may not be present in the analysis and lost in the washes. This 
confirms the importance of using other more specific tests to explore the effects of tested 
agents on apoptosis. The impact of AKBA, cisplatin, doxorubicin and either combined with 
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AKBA on Δψm were explored to be used in the present project as an indicator of the induced 
apoptosis. 
The use of Δψm as an indicator of mitochondrial health and as a marker of apoptosis is valid 
due to the direct and indirect involvement of mitochondria in several cellular processes, such 
as heat generation, redox and pH microenvironments regulation, proliferation and cell death, 
and for the inherited function of mitochondria in the intrinsic apoptotic pathway (Suzuki-
Karasaki, Ochiai and Suzuki-Karasaki, 2014; Zorova et al., 2018; Sivandzade, Bhalerao and 
Cucullo, 2019). Confirming the observations in sub-G1, AKBA led to mitochondrial 
depolarisation indicating to the involvement of impaired mitochondria in AKBA-induced 
cytotoxicity, likely through the intrinsic apoptotic pathway. This effect, similar to cell cycle, 
was observed at the high doses of AKBA at this time point (24 h) suggesting the importance 
of the time of exposure and the dose in targeting the mitochondria, which appears to be the 
two pivotal factors through the findings in this project. Further analysis of mitochondrial 
protein expression and activity could provide a better understanding of the impact of AKBA 
on mitochondria and their role in the AKBA-induced cancer cell cytotoxicity. 
NFκB pathway has emerged as one of the targeted pathways in cancer therapy in view of the 
fact that it plays critical role in tumorigenesis and tumour progression in addition to its role in 
inflammation, which is one of hallmarks of cancer, and other physiological and pathological 
processes (Hoesel and Schmid, 2013; Park and Hong, 2016; Xia et al., 2018). The anti-
inflammatory effects of boswellic acids are attributed, in part, to their ability to inhibit NFκB 
activity through suppressing IKK (Patlolla and Rao, 2011). The ability of AKBA to inhibit 
NFκB signalling was described as a potential avenue of the mechanism of actions of AKBA 
against cancer cells (Qurishi et al., 2010). It is evident, based on the NFκB pathway proteome 
profiler, that AKBA downregulates NFκB pathway by targeting a variety of proteins 
including NFκB activators, transcription factors and receptors (see chapter 4). This 
preliminary effect needs to be confirmed in further experiments with wider range of doses 
and multiple time points. Moreover, it could be beneficial to explore the impact of the agents 
on the activity of the pathway. Considering the involvement of NFκB signalling in 
tumorigenesis and tumour survival, AKBA could be further explored as an agent to either 
prevent or treat cancer since NFκB has been consistently established as one of targets of 
AKBA. It is, though, crucial to avoid long time global knockdown of NFκB considering its 
importance in inflammation and infection fighting.  
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6.2 AKBA interaction varies depending on the combined chemotherapy 
6.2.1 AKBA antagonises with cisplatin and adds to/antagonises with paclitaxel 
In this section of the chapter, the interaction of AKBA with paclitaxel or cisplatin will 
discussed. Although the EC50s of paclitaxel were improved 10 times on A2780 and 2 times on 
A2780cis, the CI values indicated for additive effect on A2780 and moderate antagonism on 
A2780cis. This observed results could be improved by increasing the exposure time to be 72 
h rather than 24 h or by examining the effect of combination of AKBA and paclitaxel on a 
paclitaxel resistant cell line, A2780/Taxol (Jin et al., 2019). This approach could be 
supported by the decreased expression of P-gp by AKBA when combined with doxorubicin, 
which was mentioned by Jin et al. (2019) as one of the reasons behind the ability of AKBA to 
sensitise A2780/Taxol to paclitaxel. Moreover, ursolic acid, a pentacyclic triterpene, 
sensitised paclitaxel resistant breast cancer cells to paclitaxel by targeting miR-149-
5p/MyD88 (Xiang et al., 2019). Even though the expression of MyD88 was low in A2780, 
AKBA reduced its expression to about the half of the untreated control (see Chapter 4). 
Cisplatin was chosen for further analysis since the antagonism with AKBA appeared higher 
than in the case of antagonism between paclitaxel and AKBA and for the problems associated 
with paclitaxel solubility and delivery such as its high affinity towards the membrane bound 
P-gp efflux pump, which contributes to the poor clinical outcomes (Gursoy et al., 2003; 
Surapaneni, Das and Das, 2012). 
The interaction between AKBA and cisplatin is antagonistic based on MTT data and CI 
values of the tested cell lines, A2780, A2780cis and OVCAR4. The antagonism between 
AKBA and cisplatin was not seen in the cell cycle analysis in A2780 at the high doses of 
cisplatin 15 and 23 µM, where cisplatin arrested cells at S phase in the presence or the 
absence of AKBA. However, the effect of cisplatin on the cell cycle at 12 µM was reduced in 
the presence of AKBA. These observations suggest that the AKBA interfere with cisplatin 
impact on the cell cycle in a dose and time dependent manner, assuming that similar effect 
with the highest doses will be recognised if the exposure was less than 24 h. In addition, the 
percentages of fragmented DNA at sub-G1 was less by about two-fold in the cells exposed to 
cisplatin combined with AKBA compared to the cells exposed to cisplatin alone.  
The impact of cisplatin alone and combined with AKBA on Nrf2 and HO-1 proteins 
expression was examined. Both AKBA alone and cisplatin alone have not affected the 
expression of the proteins at 24 h, whereas cisplatin decreased their expression at 1 h. 
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Knocking down Nrf2 or inhibiting its activity could be used in the future to test its 
involvement in the antagonistic interaction between AKBA and cisplatin, which may then 
result in improving their cytotoxicity. Finally, Changing the treatment approach from co-
exposure to pre-exposure was suggested as a possible solution, in theory (Sirota, Gibson and 
Kohen, 2017), to overcome the reported antagonism and more importantly may enhance 
cisplatin cytotoxicity leading to synergistic interaction between AKBA and cisplatin. 
 
6.2.2 Sensitising ovarian cancer cells to doxorubicin using AKBA 
In another attempt to establish the possible interaction between AKBA and chemotherapeutic 
agents, AKBA remarkably enhanced the cytotoxicity of doxorubicin against all tested cell 
lines, A2780, A2780cis, A2780ADR and OVCAR4. This, interestingly, includes sensitizing 
the resistant cell line A2780ADR to doxorubicin. This synergistic interaction between AKBA 
and doxorubicin could be attributed to the fact that both agents target multiple mechanisms 
on their own or combined (Figure 6.1). The first explored mutual targeted mechanism was 
the cell cycle, where arresting cell cycle at G2/M phase by doxorubicin was not affected by 
the presence or the absence of AKBA. 
On the other hand, AKBA altered the effect of doxorubicin on Δψm from no effect/apparent 
hyperpolarisation to depolarisation, which may mean that both induce apoptosis through 
disrupting the mitochondria, which activates the intrinsic apoptotic pathway (Ly, Grubb and 
Lawen, 2003; Gaafary et al., 2014). The other possible target pathway is NFκB pathway, 
where the expression of a number of proteins were affected by both agents. The crosstalk 
between mitochondrial ROS and depolarisation was found to selectively induce the extrinsic 
apoptotic pathway in cancer cells through upregulating TRAIL protein expression, which 
binds to TRAIL R2/DR5 (Suzuki-Karasaki, Ochiai and Suzuki-Karasaki, 2014). Further 
analysis to determine the exact role and key players of NFκB components in the synergistic 
interaction between AKBA and doxorubicin is required. NFκB knockout using 
CRISPR/CAS9-mediated gene editing (Wang et al., 2018) could reveal the function of other 
members of the pathway in the interaction. The other recommended approach is to increase 
the range of the doses of both agents and test various times of exposure. Furthermore, 
examining NFκB pathway in A2780ADR may explain the sensitisation to doxorubicin that 
resulted from combining AKBA with doxorubicin since NFκB constitutive activation was 
linked to chemoresistance in prostate cancer (Qurishi et al., 2010).  
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Figure 6.1: A summary of the synergistic interaction between AKBA and doxorubicin. 
Finally, P-gp was one of the suggested reasons for the synergistic interaction. The effect of 
doxorubicin alone or combined with AKBA was not statistically significant at the tested 
doses and time points. It may mean that P-gp is not involved in the interaction between 
AKBA and doxorubicin or the doses and time points are not enough to reveal its role. P-gp 
activity determination or expression knock down (Norouzi-Barough et al., 2018) is a 
necessary approach test the involvement of P-gp in the synergistic interaction between 
AKBA and doxorubicin.  
These promising findings are encouraging for further investigations that could lead to use of 
AKBA or BSE as an adjuvant in cancer chemotherapy, which could also help to reduce side 
effects of chemotherapies. Exploring the involvement of other mutual targets of AKBA and 
doxorubicin, that were not examined in this project, could lead to a better understanding of 
the synergistic interaction between them. For example, inhibition of topoisomerases I and II 
was described as one of the mechanisms behind the cytotoxicity of both AKBA and 
doxorubicin against cancer cells (Syrovets et al., 2000; Mizutani et al., 2005; Ni et al., 2012; 
Zhu et al., 2016). 
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6.3 BSE and AKBA in vivo and in the clinical trials 
The anti-inflammatory effect of BSE and BAs, and the role of inflammation in tumorigenesis 
and cancer progression has encouraged researchers to investigate their potential efficacy 
against cancer as discussed throughout this project. A number of pre-clinical, on in vivo 
models, and clinical studies will be discussed here. 
A number of in vivo studies have confirmed the efficacy of various extracts, essential oils or 
single bioactive molecules, AKBA in particular, from frankincense against different types of 
cancer. Anti-cancer activities were reported on pancreatic cancer (Syrovets, Gschwend, et al., 
2005; Park et al., 2011; Ni et al., 2012), glioma (Winking et al., 2000; Conti et al., 2018), 
prostate cancer (Liu et al., 2019) and colorectal cancer (Takahashi et al., 2012; Yadav et al., 
2012; Chou et al., 2017) in animal models confirming previous findings on in vitro models. 
This was attributed to modulation of various molecular targets, such as inhibition of NFκB 
pathway, and to the induction of apoptosis in cancer cells. Despite this effort in the 
mentioned examples of in vivo studies, the promising anti-cancer activity of BSE deserves 
further investigation in a hope of translating this into clinical use to help in the treatment of 
cancer. 
With regards to clinical trials, a handful of clinical trials were carried out on the effect of 
BSE on chronic diseases, mainly inflammatory conditions. In a review by Roy et al., (2019), 
BSE in clinical trials was effective on the following diseases: osteoarthritis, knee arthritis, 
gonarthrosis, brain tumour related oedema, photoaged skin, Crohn’s disease, diabetes 
erythematous eczema and asthma. Importantly, this was combined with indications that BSE 
is safe and no serious side effects were reported in a number of studies (Liu et al., 2002; 
Moussaieff and Mechoulam, 2009; Azadmehr et al., 2014; Roy et al., 2019). It is hard to find 
clinical trials of BSE on cancer. The nearest form of clinical use of BSE on cancer is a case 
report of a successfully treated basal-cell carcinoma of the skin by a topical application of 
frankincense essential oil that was extracted by hydrodistillation (Fung et al., 2013). There 
seems to be a lack of clinical trials, especially on cancer, combined with insufficient in vivo 
studies even though frankincense has been shown to possess promising anti-tumour 
properties on a broad range of cancer models. Further investigations of the possible 
applications of BSE on cancer in pre-clinical and clinical settings are needed taking into 




This project demonstrates the potential anti-tumour activity of BSE and AKBA, against 
ovarian cancer in particular. This confirms similar observations reported on other cancers. 
The interaction between AKBA and chemotherapies seems to be dependent on a number of 
factors including cell line, time of exposure and doses of AKBA or the doses of a standard 
chemotherapeutic drug. The key observation is the ability of AKBA to remarkably improve 
the cytotoxicity of doxorubicin towards ovarian cancer, including sensitising the resistant 
cells to doxorubicin. The combination of AKBA with doxorubicin could lead to a novel 
treatment strategies for ovarian cancer that could help in reducing the side effects of 
doxorubicin and improving its efficacy. 
 
6.5 Limitations and future work  
The first limitation to note is the range of doses or time points used in the experiments. A 
wider range could provide a better understanding. For example, testing the effect of AKBA 
on the cell cycle at different time points, i.e. 1, 6, 12, 48, 72 h, could help in revealing the 
time where a specific dose of AKBA triggers changes in the cell cycle, which in turn helps in 
future mechanistic exploration when examining involved molecular changes such as the 
expression of proteins involved in the cell cycle regulation. The other limiting factor that is 
linked to this point is using a single dose of AKBA, that reduces cell viability to 60/70 %, 
especially in the agent interaction experiments and mechanistic experiments. The same 
applies for other experiments performed in this project. 
With regards to protein expression experiments, it would have been useful to collect samples 
in a different way to gather proteins in the extracellular environment (the medium) rather 
than cellular proteins alone.  
Using adherent cell culture (two-dimensional, 2D) in this project is a reason that may restrict 
some conclusions drawn. One of the suggestions to overcome this limitation is using three-
dimensional (3D) ovarian cell culture model (spheroids), which is considered as a relatively 
better in vitro model (Yang and Zhao, 2011). It is reported that 3D cell culture model of 
ovarian cancer showed alterations in the protein expression and more resistance to 
chemotherapies, which suggests that 3D cell culture is superior model in in terms of 
mimicking the in vivo conditions compared to conventional 2D cell culture (Yang and Zhao, 
2011; Lee et al., 2013). 
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Findings of the present project on the potent toxicity of BSE and AKBA on ovarian cancer 
combined with the dual interaction of AKBA with chemotherapies, in particular the 
synergism with doxorubicin, confirm previously published data on other cancer types. This 
warrant further pre-clinical investigations, which form the basis for future clinical trials. Here 
is a number of suggestions for future work: 
• Further mechanistic analysis is required to confirm and understand the molecular 
events behind the reported interaction between AKBA and doxorubicin. 
• The toxicity of doxorubicin was enhanced by combining single dose of AKBA, it is 
interesting to explore whether the toxicity of AKBA will be enhanced by 
doxorubicin. 
• After establishing the potential anti-tumour activity of the ethanol extract in this 
project, various extracts of frankincense could be further investigated in combination 
with selected chemotherapies. 
• Similar approaches of treatments using AKBA or BSE alone or combined with 
chemotherapies could be applied on 3D cell culture or on in vivo models.  
• Pre-clinical studies to establish ADME (absorption, distribution, metabolism, and 
excretion) and pharmacokinetics (PK) are vital prior phase I clinical trials in humans. 
• Since stem cells play critical role in chemoresistance, it could be beneficial to 
investigate the effect of BSE or AKBA alone or combined with chemotherapies on 
CD44+/MyD88 ovarian cancer stem cells (Alvero et al., 2011). This could open new 
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Thin layer chromatography (TLC) 
To conduct a preliminary examination of the presence of AKBA in the frankincense extracts, 
TLC was used. Fluorescent TLC plates were used and the mobile phase consisted of 7 parts 
of hexane, 3 parts of ethyl acetate and one drop of formic acid. A spot of the oily component 
and the clear phase of the 70 % ethanol extract, and a drop of pure AKBA (9.75 mM) were 
placed on the TLC plate, about 1 cm from the bottom of the plate. The plate was put in the 
chromatography tank and the plate run until the solvent was approximately 0.5 cm from the 
top of the plate, the solvent front was marked and the solvent allowed to dry. The plate was 
placed in a mini UV viewing cabinet (UVP, model: C-10, Cambridge, UK) to mark the 
AKBA position and compare to the component from the two examined extracts. To be able to 
visualise AKBA and other compounds by naked eye, the plate was sprayed using 
anisaldehyde spray which is composed of 0.5 mL anisaldehyde, 85 mL methanol, 10 mL 
acetic acid and 5 mL sulphuric acid. 
TLC chromatogram 
The presence of AKBA in the purified extracts was tested using TLC. The possible presence 
of AKBA wasn noted in addition to other un-identified compounds separated in both extracts. 
Retention factors (Rf) of the control AKBA (middle of spot) was 0.37. Similar Rf values were 
found in the oily and clear extracts 0.4 and 0.42, respectively (Figure 6). Further 
identification and quantification of the compounds using gas chromatography–mass 
spectrometry (GC-MS) and/or high-performance liquid chromatography (HPLC) are required 





 Figure 6: UV detection (left) and a chromatogram detection (right) of AKBA and other compounds in the extracts. 
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A. Preparation of Cells 
1. For adherent cells: Plate cells overnight in growth medium at 20,000 to 80,000 
cells/well/90 μL for a 96- well plate or 5,000 to 20,000 cells/well/20 μL for a 384- well plate. 
2. For non-adherent cells: Centrifuge the cells from the culture medium and then suspend the 
cell pellet in culture medium at 100,000-200,000 cells/well/90 μL for a 96-well poly-D lysine 
plate or 25,000 - 50,000cells/well/20 μL for a 384-well poly-D lysine plate. Centrifuge the 
plate at 800 rpm for 2 minutes with brake off prior to the experiments 
Note: Each cell line should be evaluated on the individual basis to determine the optimal cell 
density for apoptosis induction. 
B. Preparation of JC-10 dye-loading solution 
1. Thaw all the kit components at room temperature before use. 
2. Add 50 μL of 100X JC-10 (Component A) into 5 mL Assay Buffer A (Component B), and 
mix well. 
Note: Aliquot and store the unused Component A at -20°C. Avoid repeated freeze/thaw 
cycles. 
C. Run JC-10 Assay 
1. Treat cells by adding 10 μL of 10X test compounds (96- well plate) or 5 μL of 5X test 
compounds (384-plate) into the desired buffer (such as PBS or HHBS). 
Note: It is not necessary to wash cells before adding compound. However, if tested 
compounds are serum sensitive, growth medium and serum factors can be aspirated away 
before adding compounds. Add the same volume of HHBS into the wells (such as 90 μL for a 
96-well plate or 20 μL for a 384-well plate) after aspiration. Alternatively, cells can be grown 
in serum- free media. 
2. Incubate the cell plate at room temperature or in a 37 °C, 5% CO2 incubator for at least 15 
minutes or a desired period (4-6 hours for Jurkat cells treated with camptothecin) to induce 
apoptosis. 
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3. Add 50 μL/well (96-well plate) or 12.5 μL/well (384-well plate) of JC-10 dye-loading 
solution (from step B.2) into the cell plate (from Step C.2). 
4. Incubate the dye-loading plate at room temperature or in a 37°C, 5% CO2 incubator for 30 
minutes to 1 hour, protected from light. 
Note: The appropriate incubation time depends on the individual cell type and cell 
concentration used. Optimize the incubation time for each experiment. 
5. Add 50 μL/well (96-well plate) or 12.5 μL/well (384-well plate) of Assay Buffer B 
(Component C) into the dye- loading plate (from Step C.4) before reading the fluorescence 
intensity. 
Note 1: DO NOT wash the cells after loading. 
Note 2: For non-adherent cells, it is recommended to centrifuge cell plates at 800 rpm for 2 
minutes with brake off after adding Assay Buffer B (Component C). 
6. Monitor the fluorescence intensities at Ex/Em = 490/525 nm (cut off at 515 nm) and 
540/590 nm (cut off at 570 nm) for ratio analysis. 
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DR5 and cIAP1 replicates:  
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Nrf2 and HO-1 replicates n=3:  
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P-gP replicates n=3:  
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Proteome ProfilerTM Array Human NFκB Pathway Array Kit 
Protein list: 
ASC IL-18 R alpha RelA/p65 (pS529) 
BCL-10 IRAK1 c-Rel 
CARD6 IRF5 SHARPIN 
CD40/TNFRSF5 IRF8 SOCS-6 
dAP1/BIRC2 JNK1/2 STAT1p91 
dAP2/BIRC3 JNK2 STAT1 (pY701) 
FADD/MORT1 LTBR/TNFRSF3 STAT2 
Fas/TNFRSF6/CD95 Metadherin/AEG-1 STAT2 (pY689) 
IκBα MYD88 STING/TMEM173 
IκBε NFκB1 TLR2 
IKK1/IKKα/CHUK NFκB2 TNF RI/TNFRSF1A 
IKK2/IKKβ NGF R/TNFRSF16 TNF RII/TNFRSF1B 
IKKυ/NEMO P53 TRAF2 
IL-1 RI P53 (pS46) TRAIL R1/DR4 
IL-17 RA RelA/p65 TRAIL R2/DR5 
 150 
ARRAY PROCEDURE  
Bring all reagents to room temperature before use. Keep samples on ice. To avoid 
contamination, wear gloves while performing the procedures.  
1. Prepare all reagents and samples as directed in the previous sections.  
2. Pipette 2.0 mL of Array Buffer 3/6 into each well of the 4-Well Multi-dish to 
be used. Array Buffer 3/6 serves as a block buffer.  
3. Using flat-tip tweezers, remove each membrane to be used from between the 
protective sheets and place in a well of the 4-Well Multi-dish. The array 
number should be facing upward.  
Note: Upon contact with Array Buffer 3/6, the blue dye from the spots will 
disappear, but the capture antibodies are retained in their specific locations.  
4. Incubate for one hour on a rocking platform shaker. Orient the tray so that each 
array rocks end to end in its well.  
5. While the membranes are blocking, prepare samples by adding the desired 
quantity of lysate to Array Buffer 1 for a total volume of 1.5 mL. Maximum 
lysate volume is 250 μL.  
6. Aspirate Array Buffer 3/6 from the wells of the 4-Well Multi-dish. Add 
prepared samples and place the lid on the 4-Well Multi-dish.  
7. Incubate overnight at 2-8 °C on a rocking platform.  
Note: A shorter incubation time may be used if optimal sensitivity is not 
required.  
8. Carefully remove each membrane and place into individual plastic containers 
with 20 mL of 1X Wash Buffer. Rinse the 4-Well Multi-dish with deionized or 
distilled water and dry thoroughly.  
9. Wash each membrane with 1X Wash Buffer for 10 minutes on a rocking 
platform shaker. Repeat two times for a total of three washes.  
10. For each array, dilute 15 μL of reconstituted Detection Antibody Cocktail to 
1.5 mL with Array Buffer 3/6. Pipette 1.5 mL per well of diluted Detection 
Antibody Cocktail into the 4-Well Multi-dish.  
11. Carefully remove each membrane from its wash container. Allow excess buffer 
to drain from the membrane. Return the membrane to the 4-Well Multi-dish 
containing the diluted Detection Antibody Cocktail. Cover the wells with the 
lid.  
12. Incubate for 1 hour at room temperature on a rocking platform shaker.  
13. Wash each array as described in steps 8 and 9.  
14. Dilute the Streptavidin-HRP in Array Buffer 3/6 using the dilution factor on the 
vial label. Pipette 2.0 mL into each well of the 4-Well Multi-dish.  
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15. Carefully remove each membrane from the wash container. Allow excess Wash 
Buffer to drain from the membrane. Return the array to the 4-Well Multi-dish 
containing the diluted Streptavidin-HRP, and cover with the lid. Incubate for 30 
minutes on a rocking platform shaker.  
16. Wash each array as described in steps 8 and 9.  
Note: Complete the remaining steps without interruption.  
17. Carefully remove each membrane from its wash container. Allow excess Wash 
Buffer to drain from the membrane by blotting the lower edge onto paper 
towels. Place each membrane on the bottom sheet of the plastic sheet protector 
with the identification number facing up.  
18. Pipette 1 mL of the prepared Chemi Reagent Mix evenly onto each membrane.  
Note: Using less than 1 mL of Chemi Reagent Mix per membrane may result in 
incomplete membrane coverage.  
19. Carefully cover with the top sheet of the plastic sheet protector. Gently smooth 
out any air bubbles and ensure Chemi Reagent Mix is spread evenly to all 
corners of each membrane. Incubate for 1 minute.  
20. Position paper towels on the top and sides of the plastic sheet protector 
containing the membranes and carefully squeeze out excess Chemi Reagent 
Mix.  
21. Remove the top plastic sheet protector and carefully lay an absorbent lab wipe 
on top of the membranes to blot off any remaining Chemi Reagent Mix.  
22. Leaving membranes on the bottom plastic sheet protector, cover the 
membranes with plastic wrap taking care to gently smooth out any air bubbles. 
Wrap the excess plastic wrap around the back of the sheet protector so that the 
membranes and sheet protector are completely wrapped.  
23. Place the membranes with the identification numbers facing up in an 
autoradiography film cassette.  
Note: Use an autoradiography cassette that is not used with radioactive 
isotope detection.  
24. Expose membranes to X-ray film for 1-10 minutes. Multiple exposure times 
are recommended.  
(https://resources.rndsystems.com/pdfs/datasheets/ary029.pdf) 
